<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical lower limb ischaemia patients - Abdul Wahid, SF - 2018 | Cochrane Library</title> <meta content="Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical lower limb ischaemia patients - Abdul Wahid, SF - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010747.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical lower limb ischaemia patients - Abdul Wahid, SF - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010747.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010747.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical lower limb ischaemia patients" name="citation_title"/> <meta content="S Fadilah Abdul Wahid" name="citation_author"/> <meta content="sfadilah@ppukm.ukm.edu.my" name="citation_author_email"/> <meta content="Nor Azimah Ismail" name="citation_author"/> <meta content="Universiti Kebangsaan Malaysia Medical Centre" name="citation_author_institution"/> <meta content="Wan Fariza Wan Jamaludin" name="citation_author"/> <meta content="Universiti Kebangsaan Malaysia Medical Centre" name="citation_author_institution"/> <meta content="Nor Asiah Muhamad" name="citation_author"/> <meta content="Ministry of Health" name="citation_author_institution"/> <meta content="Muhammad Khairul Azaham Abdul Hamid" name="citation_author"/> <meta content="Universiti Kebangsaan Malaysia Medical Centre" name="citation_author_institution"/> <meta content="Hanafiah Harunarashid" name="citation_author"/> <meta content="Universiti Kebangsaan Malaysia Medical Centre" name="citation_author_institution"/> <meta content="Nai Ming Lai" name="citation_author"/> <meta content="Taylor's University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD010747.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/08/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010747.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010747.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010747.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amputation, Surgical [statistics &amp; numerical data]; Bone Marrow Cells [cytology]; Bone Marrow Transplantation [*methods]; Cause of Death; Injections, Intra-Arterial; Injections, Intramuscular; Ischemia [*therapy]; Leg [*blood supply]; Leg Ulcer [therapy]; Mesenchymal Stem Cell Transplantation [*methods]; Peripheral Blood Stem Cell Transplantation [*methods]; Peripheral Blood Stem Cells [cytology]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010747.pub2&amp;doi=10.1002/14651858.CD010747.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="0TJL4CWK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010747\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010747\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","fr","zh_HANS","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010747.pub2",title:"Autologous cells derived from different sources and administered using different regimens for \u0027no\\u2010option\u0027 critical lower limb ischaemia patients",firstPublishedDate:"Aug 29, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010747.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010747.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010747.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010747.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010747.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010747.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010747.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010747.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010747.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010747.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2011 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010747.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-sec-0143"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-sec-0049"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-sec-0050"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-sec-0075"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-sec-0137"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/appendices#CD010747-sec-0148"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/table_n/CD010747StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/table_n/CD010747StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical lower limb ischaemia patients </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information#CD010747-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>S Fadilah Abdul Wahid</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information#CD010747-cr-0003">Nor Azimah Ismail</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information#CD010747-cr-0004">Wan Fariza Wan Jamaludin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information#CD010747-cr-0005">Nor Asiah Muhamad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information#CD010747-cr-0006">Muhammad Khairul Azaham Abdul Hamid</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information#CD010747-cr-0007">Hanafiah Harunarashid</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information#CD010747-cr-0008">Nai Ming Lai</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information/en#CD010747-sec-0154">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 August 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010747.pub2">https://doi.org/10.1002/14651858.CD010747.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010747-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010747-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010747-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010747-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010747-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010747-abs-0002">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010747-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010747-abs-0001" lang="en"> <section id="CD010747-sec-0001"> <h3 class="title" id="CD010747-sec-0001">Background</h3> <p>Revascularisation is the gold standard therapy for patients with critical limb ischaemia (CLI). In over 30% of patients who are not suitable for or have failed previous revascularisation therapy (the 'no‐option' CLI patients), limb amputation is eventually unavoidable. Preliminary studies have reported encouraging outcomes with autologous cell‐based therapy for the treatment of CLI in these 'no‐option' patients. However, studies comparing the angiogenic potency and clinical effects of autologous cells derived from different sources have yielded limited data. Data regarding cell doses and routes of administration are also limited. </p> </section> <section id="CD010747-sec-0002"> <h3 class="title" id="CD010747-sec-0002">Objectives</h3> <p>To compare the efficacy and safety of autologous cells derived from different sources, prepared using different protocols, administered at different doses, and delivered via different routes for the treatment of 'no‐option' CLI patients. </p> </section> <section id="CD010747-sec-0003"> <h3 class="title" id="CD010747-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist (CIS) searched the Cochrane Vascular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid, Embase Ovid, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED), and trials registries (16 May 2018). Review authors searched PubMed until February 2017. </p> </section> <section id="CD010747-sec-0004"> <h3 class="title" id="CD010747-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) involving 'no‐option' CLI patients comparing a particular source or regimen of autologous cell‐based therapy against another source or regimen of autologous cell‐based therapy. </p> </section> <section id="CD010747-sec-0005"> <h3 class="title" id="CD010747-sec-0005">Data collection and analysis</h3> <p>Three review authors independently assessed the eligibility and methodological quality of the trials. We extracted outcome data from each trial and pooled them for meta‐analysis. We calculated effect estimates using a risk ratio (RR) with 95% confidence interval (CI), or a mean difference (MD) with 95% CI. </p> </section> <section id="CD010747-sec-0006"> <h3 class="title" id="CD010747-sec-0006">Main results</h3> <p>We included seven RCTs with a total of 359 participants. These studies compared bone marrow‐mononuclear cells (BM‐MNCs) versus mobilised peripheral blood stem cells (mPBSCs), BM‐MNCs versus bone marrow‐mesenchymal stem cells (BM‐MSCs), high cell dose versus low cell dose, and intramuscular (IM) versus intra‐arterial (IA) routes of cell implantation. We identified no other comparisons in these studies. We considered most studies to be at low risk of bias in random sequence generation, incomplete outcome data, and selective outcome reporting; at high risk of bias in blinding of patients and personnel; and at unclear risk of bias in allocation concealment and blinding of outcome assessors. The quality of evidence was most often low to very low, with risk of bias, imprecision, and indirectness of outcomes the major downgrading factors. </p> <p>Three RCTs (100 participants) reported a total of nine deaths during the study follow‐up period. These studies did not report deaths according to treatment group. </p> <p>Results show no clear difference in amputation rates between IM and IA routes (RR 0.80, 95% CI 0.54 to 1.18; three RCTs, 95 participants; low‐quality evidence). Single‐study data show no clear difference in amputation rates between BM‐MNC‐ and mPBSC‐treated groups (RR 1.54, 95% CI 0.45 to 5.24; 150 participants; low‐quality evidence) and between high and low cell dose (RR 3.21, 95% CI 0.87 to 11.90; 16 participants; very low‐quality evidence). The study comparing BM‐MNCs versus BM‐MSCs reported no amputations. </p> <p>Single‐study data with low‐quality evidence show similar numbers of participants with healing ulcers between BM‐MNCs and mPBSCs (RR 0.89, 95% CI 0.44 to 1.83; 49 participants) and between IM and IA routes (RR 1.13, 95% CI 0.73 to 1.76; 41 participants). In contrast, more participants appeared to have healing ulcers in the BM‐MSC group than in the BM‐MNC group (RR 2.00, 95% CI 1.02 to 3.92; one RCT, 22 participants; moderate‐quality evidence). Researchers comparing high versus low cell doses did not report ulcer healing. </p> <p>Single‐study data show similar numbers of participants with reduction in rest pain between BM‐MNCs and mPBSCs (RR 0.99, 95% CI 0.93 to 1.06; 104 participants; moderate‐quality evidence) and between IM and IA routes (RR 1.22, 95% CI 0.91 to 1.64; 32 participants; low‐quality evidence). One study reported no clear difference in rest pain scores between BM‐MNC and BM‐MSC (MD 0.00, 95% CI ‐0.61 to 0.61; 37 participants; moderate‐quality evidence). Trials comparing high versus low cell doses did not report rest pain. </p> <p>Single‐study data show no clear difference in the number of participants with increased ankle‐brachial index (ABI; increase of &gt; 0.1 from pretreatment), between BM‐MNCs and mPBSCs (RR 1.00, 95% CI 0.71 to 1.40; 104 participants; moderate‐quality evidence), and between IM and IA routes (RR 0.93, 95% CI 0.43 to 2.00; 35 participants; very low‐quality evidence). In contrast, ABI scores appeared higher in BM‐MSC versus BM‐MNC groups (MD 0.05, 95% CI 0.01 to 0.09; one RCT, 37 participants; low‐quality evidence). ABI was not reported in the high versus low cell dose comparison. </p> <p>Similar numbers of participants had improved transcutaneous oxygen tension (TcO₂) with IM versus IA routes (RR 1.22, 95% CI 0.86 to 1.72; two RCTs, 62 participants; very low‐quality evidence). Single‐study data with low‐quality evidence show a higher TcO₂ reading in BM‐MSC versus BM‐MNC groups (MD 8.00, 95% CI 3.46 to 12.54; 37 participants) and in mPBSC‐ versus BM‐MNC‐treated groups (MD 1.70, 95% CI 0.41 to 2.99; 150 participants). TcO₂ was not reported in the high versus low cell dose comparison. </p> <p>Study authors reported no significant short‐term adverse effects attributed to autologous cell implantation. </p> </section> <section id="CD010747-sec-0007"> <h3 class="title" id="CD010747-sec-0007">Authors' conclusions</h3> <p>Mostly low‐ and very low‐quality evidence suggests no clear differences between different stem cell sources and different treatment regimens of autologous cell implantation for outcomes such as all‐cause mortality, amputation rate, ulcer healing, and rest pain for 'no‐option' CLI patients. Pooled analyses did not show a clear difference in clinical outcomes whether cells were administered via IM or IA routes. High‐quality evidence is lacking; therefore the efficacy and long‐term safety of autologous cells derived from different sources, prepared using different protocols, administered at different doses, and delivered via different routes for the treatment of 'no‐option' CLI patients, remain to be confirmed. </p> <p>Future RCTs with larger numbers of participants are needed to determine the efficacy of cell‐based therapy for CLI patients, along with the optimal cell source, phenotype, dose, and route of implantation. Longer follow‐up is needed to confirm the durability of angiogenic potential and the long‐term safety of cell‐based therapy. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010747-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010747-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010747-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010747-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010747-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010747-abs-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010747-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010747-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010747-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010747-abs-0005" lang="en"> <h3>Cell‐based therapy using different sources and different treatment regimens for 'no‐option' CLI patients </h3> <p><b>Background</b> </p> <p>Critical limb ischaemia (CLI) is characterised by severe leg pain on walking and at rest and hard‐to‐heal wounds, which may lead to disability and death. The procedure that aims to improve blood flow to the affected limb, known as 'revascularisation', is the gold standard therapy. However, 25% to 40% of people with CLI are not suitable for or have failed previous revascularisation therapy. Therefore, for these patients, the only option for relieving pain and stopping wound infection from spreading is limb amputation. These patients are commonly referred to as 'no‐option' CLI patients. </p> <p>Cell‐based therapy is increasingly recognised as a promising novel treatment for CLI. Most of the data for this novel approach have been obtained from studies based on patients' own cells, also known as 'autologous cells'. However, current data on the efficacy of autologous cells are limited because available information about the sources used to obtain these cells (e.g. bone marrow, peripheral blood), the doses used (e.g. high or low cell dose), and the method of cell administration selected (e.g. cell injection into muscles or into blood vessels) is limited. In this review, we evaluated the efficacy and safety of autologous cell‐based therapy derived from different sources and prepared as different treatment regimens for 'no‐option' CLI patients. </p> <p><b>Study characteristics and key results</b> </p> <p>We analysed the findings of seven randomised controlled trials (RCTs) involving 359 CLI patients revealed by our literature search, which was current to 16 May 2018. </p> <p>We evaluated two main sources of stem cell treatment, namely, 'bone marrow‐mononuclear cells (BM‐MNCs)' and 'mobilised peripheral blood stem cells (mPBSCs)'. Limited data suggest that BM‐MNCs or mPBSCs resulted in similar rates of limb amputation and death. Also, the two cell sources appeared to yield similar numbers of patients with improved rest pain, ulcer healing, and lower limb blood flow parameters as measured via the ankle‐brachial index (ABI). However, data from one RCT show that mPBSC implantation resulted in improved transcutaneous oxygen tension (TcO₂) readings when compared to BM‐MNC. Data from one RCT show no clear difference in amputation rates between patients receiving high cell dose and low cell dose, and no difference in clinical outcomes whether patients received cell doses via intramuscular or intra‐articular routes. Study authors reported no significant short‐term adverse effects attributed to autologous cell implantation. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of evidence for all outcomes varied but was mostly low to very low owing to limitations in study design and lack of data for several important outcomes. Taken together, there is insufficient high‐quality evidence to assess the effects of using a particular source or treatment regimen of cell‐based therapy for CLI in clinical practice. Larger trials with longer follow‐up are needed to evaluate the long‐term benefits and safety of various cell‐based products for patients with CLI. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010747-sec-0143" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010747-sec-0143"></div> <h3 class="title" id="CD010747-sec-0144">Implications for practice</h3> <section id="CD010747-sec-0144"> <p>Evidence of mostly low and very low quality shows no clear differences between different sources, cell doses, and implantation routes for cell‐based therapy among patients with CLI in terms of mortality, amputation rate, rest pain, ulcer healing, and lower limb perfusion. Cell therapy appeared to be well tolerated without serious adverse events arising from cell harvesting from bone marrow or peripheral blood and cell implantation into the ischaemic limb. Overall the efficacy and long‐term safety of autologous cells derived from different sources, prepared using different protocols, administered at different doses, and delivered via different routes for treatment of 'no‐option' CLI patients, remain to be confirmed. Underpowered analyses have precluded any firm conclusions that may influence practice. </p> </section> <h3 class="title" id="CD010747-sec-0145">Implications for research</h3> <section id="CD010747-sec-0145"> <p>Authors of the current review could not draw definitive conclusions on the efficacy of different sources, types, and treatment regimens of cell‐based therapy for CLI patients, and high‐quality clinical trials are urgently needed to answer these clinical questions. In particular, the long‐term safety of cell‐based products derived from different sources, prepared using different protocols, and administered at different doses and via different routes, needs to be determined. Future clinical trials should consider the following factors. </p> <p> <ol id="CD010747-list-0011"> <li> <p>Larger sample size with adequate blinding of study population and personnel.</p> </li> <li> <p>Head‐to‐head comparison between cell‐based treatment derived from different sources via different cell preparation protocols, routes of cell delivery, cell doses, and implantation regimens. </p> </li> <li> <p>Determination of clinical endpoints according to underlying aetiologies, risk factors (smoking, diabetes, age group, and gender), and severity of PAD, with separate analyses and reporting of results according to these subgroups. </p> </li> <li> <p>Long‐term follow‐up to evaluate the durability of angiogenic potential and the long‐term safety of cell‐based therapy. </p> </li> <li> <p>Use of angiogenic growth factors, cell carriers, and other adjunctive therapies in combination with cell‐based treatment. </p> </li> <li> <p>Comparison of the safety and efficacy of allogeneic cell therapy versus autologous cell therapy. </p> </li> <li> <p>Comparison of the cost of therapy amongst different cell‐based treatment modalities.</p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010747-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010747-sec-0043"></div> <div class="table" id="CD010747-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">BM‐MNCs compared to mPBSCs for critical lower limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Is BM‐MNC implantation more effective than mPBSC implantation for reducing all‐cause mortality, amputation rate, number of participants with any reduction in rest pain score, and number of healing ulcers and for improving lower limb perfusion in people with critical lower limb ischaemia?</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with critical lower limb ischaemia </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> BM‐MNCs </p> <p><b>Comparison:</b> mPBSCs </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mPBSCs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with BM‐MNCs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality</p> <p>Assessed during in‐patient stay</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths were reported by the 2 studies in this comparison (<a href="https://archie.cochrane.org/sections/documents/view?version=z1805300810164174096369342618414%26format=REVMAN#STD-Huang-2007" target="_blank">Huang 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1805300810164174096369342618414%26format=REVMAN#STD-Zhang-2009" target="_blank">Zhang 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Amputation rate</p> <p>Assessed during in‐patient stay</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.54</p> <p>(0.45 to 5.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>150</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/> (24 to 276) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> <p>(24 to 276)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Wound/ulcer healing: number of participants with healing ulcers</p> <p>Assessed during in‐patient stay</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.89</p> <p>(0.44 to 1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>49</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>407 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>363 per 1000</p> <p>(179 to 746)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>407 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>363 per 1000</p> <p>(179 to 746)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Reduction in rest pain: number of participants with any reduction in rest pain score</p> <p>Assessed during in‐patient stay</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.99<br/> (0.93 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>977 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>968 per 1000</p> <p>(909 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>977 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>968 per 1000<br/> (909 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Improvement in lower limb perfusion: number of participants with increased ABI</p> <p>Assessed at 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.00<br/> (0.71 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000<br/> (403 to 795) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000<br/> (369 to 744) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in lower limb perfusion: TcO₂ reading in mmHg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean TcO₂ reading in mmHg was 4.68.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean TcO₂ reading in the intervention group was 1.7 mmHg more (0.41 more to 2.99 more).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The study included in this comparison reported the TcO₂ reading in mmHg, not the number of participants with improvement in lower limb perfusion, which was our preferred outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>** We took the median control group event rate for the outcome as "moderate risk".</b> </p> <p>ABI: ankle‐brachial index; BM‐MNCs: bone marrow‐mononuclear cells; CI: confidence interval; mPBSCs: mobilised peripheral blood stem cells; RCT: randomised controlled trial; RR: risk ratio; TcO₂: transcutaneous oxygen tension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different </p> <p><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect </p> <p><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The single included study had unclear risk of selection bias and high risk of performance bias (patients and personnel were not blinded). Quality of evidence was downgraded by one level.<br/> <sup>b</sup>The 95% CI is wide, as it ranges from substantial benefits favouring BM‐MNCs to substantial benefits favouring mPBSCs. Quality of evidence was downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010747-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">BM‐MNCs compared to BM‐MSCs for critical lower limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Is BM‐MNC implantation more effective than BM‐MSC implantation for reducing all‐cause mortality, amputation rate, number of participants with any reduction in rest pain score, and number of healing ulcers and for improving lower limb perfusion in patients with critical lower limb ischaemia?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical lower limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> BM‐MNCs<br/> <b>Comparison:</b> BM‐MSCs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with BM‐MSCs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with BM‐MNCs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Assessed during in‐patient stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths were reported by the single study included in this comparison (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amputation rate</p> <p>Assessed during in‐patient stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No amputations were reported by the single study included in this comparison (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Wound/ulcer healing: number of participants with healing ulcers</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 2.00<br/> (1.02 to 3.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>909 per 1000<br/> (464 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Moderate**</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>909 per 1000<br/> (464 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in rest pain: rest pain score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean rest pain score was 1.4.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean rest pain score in the intervention group was similar (0) (0.61 fewer to 0.61 more). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study included in this comparison reported the rest pain score, not the number of participants with improved rest pain, which was our preferred outcome. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in lower limb perfusion: ABI score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ABI score was 0.12.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ABI score in the intervention group was 0.05 more (0.01 more to 0.09 more).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study included in this comparison reported the ABI score, not the number of participants with improvement in lower limb perfusion, which was our preferred outcome. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in lower limb perfusion: TcO₂ reading in mmHg</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TcO₂ reading in mmHg was 16.4.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TcO₂ reading in the intervention group was 8 mmHg more (3.46 more to 12.54 more).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study included in this comparison reported the TcO₂ reading in mmHg, not the number of participants with improvement in lower limb perfusion, which was our preferred outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>** We took the median control group event rate for the outcome as "moderate risk".</b><br/> ABI: ankle‐brachial index; BM‐MNCs: bone marrow mononuclear cells; BM‐MSCs: bone marrow mesenchymal stem cells; CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; TcO₂: transcutaneous oxygen tension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The effect estimate of a single small study ranges from slight benefit to substantial benefit favouring BM‐MSCs. Quality of evidence was downgraded by one level.<br/> <sup>b</sup>The effect estimate of a single small study ranges from substantial benefit favouring BM‐MNCs to substantial benefit favouring BM‐MSCs. Quality of evidence was downgraded by one level.<br/> <sup>c</sup>ABI score is not a clinical outcome, and its correlation with clinical symptoms and functions is unclear. Quality of evidence was downgraded by one level.<br/> <sup>d</sup>The effect estimate of a single small study ranges from slight to substantial benefit for the intervention group in terms of the outcome measured (ABI score and TcO₂ reading, respectively). Quality of evidence was downgraded by one level for each outcome concerned.<br/> <sup>e</sup>TcO₂ reading is not a clinical outcome, and its correlation with clinical symptoms and functions is unclear. Quality of evidence was downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010747-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High cell dose compared to low cell dose for critical lower limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Is high cell dose more effective than low cell dose for reducing all‐cause mortality, amputation rate, number of participants with any reduction in rest pain score, and number of healing ulcers and for improving lower limb perfusion in patients with critical lower limb ischaemia?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical lower limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> high cell dose<br/> <b>Comparison:</b> low cell dose </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low cell dose</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with high cell dose</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Assessed during in‐patient stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths were reported by the single RCT included in this comparison (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Amputation rate</p> <p>Assessed during in‐patient stay</p> <p>(<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 3.21 (0.87 to 11.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>16 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>713 per 1000 (193 to 1000)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>713 per 1000 (193 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wound ulcer healing</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported by the single RCT included in this comparison (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reduction in rest pain</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported by the single RCT included in this comparison (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in lower limb perfusion: ABI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported by the single RCT included in this comparison (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in lower limb perfusion: TcO₂</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported by the single RCT included in this comparison (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>** We took the median control group event rate for the outcome as "moderate risk".</b><br/> ABI: ankle‐brachial index; CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; TcO₂: transcutaneous oxygen tension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The 95% CI of the effect estimate is extremely wide, covering both sides of the no‐effect line. Quality of evidence was downgraded by two levels on the basis of imprecision.<br/> <sup>b</sup>The single included study had unclear risk of selection bias and high risk of selection bias and unclear risk of performance and detection biases, attrition bias, and reporting bias. Quality of evidence was downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010747-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">IM injection compared to IA injection for critical lower limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Is IM cell implantation more effective than IA cell implantation for reducing all‐cause mortality, amputation rate, number of participants with any reduction in rest pain score, and number of healing ulcers and for improving lower limb perfusion in patients with critical lower limb ischaemia?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical lower limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> IM injection<br/> <b>Comparison:</b> IA injection </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IA injection</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IM injection</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Assessed during in‐patient stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three RCTs with a total of 100 participants reported 9 deaths (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>). None of the 3 studies reported all‐cause mortality according to treatment group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Amputation rate</p> <p>Assessed during in‐patient stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.80<br/> (0.54 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>95<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000<br/> (270 to 590) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>636 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>509 per 1000<br/> (344 to 751) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Wound/ulcer healing: number of participants with healing ulcer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.13<br/> (0.73 to 1.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>619 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000<br/> (452 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>619 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>699 per 1000<br/> (452 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Reduction in rest pain: number of participants with reduction in rest pain score</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.22<br/> (0.91 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>32<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>765 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>933 per 1000<br/> (696 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>765 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>933 per 1000<br/> (696 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Improvement in lower limb perfusion: number of participants with increased ABI</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.93<br/> (0.43 to 2.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1000<br/> (191 to 889) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41</p> <p>3 per 1000<br/> (191 to 889) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Improvement in lower limb perfusion: number of participants with improved TcO₂ reading</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.22<br/> (0.86 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>62<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>613 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>748 per 1000<br/> (527 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>603 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>735 per 1000<br/> (518 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>** We took the median control group event rate for the outcome as "moderate risk".</b><br/> ABI: ankle‐brachial index; CI: confidence interval; IA: intra‐arterial; IM: intramuscular; RCT: randomised controlled trial; RR: risk ratio; TcO₂: transcutaneous oxygen tension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>All three included studies had unclear risk of selection bias and high risk of performance biases (participants and personnel were not blinded). Quality of evidence was downgraded by one level.<br/> <sup>b</sup>The 95% CI for the effect estimate from a single small study ranges from an effect size that clearly favours IM injection to an effect size that clearly favours IA injection. Quality of evidence was downgraded by one level on the basis of imprecision.<br/> <sup>c</sup>The single included study had unclear risk of selection bias and high risk of performance bias (participants and personnel were not blinded). Quality of evidence was downgraded by one level.<br/> <sup>d</sup>An improvement in ABI might not correlate strongly with an improvement in clinical symptoms and functions. Quality of evidence was downgraded by one level.<br/> <sup>e</sup>The two included studies had unclear risk of selection bias and high risk of performance bias (participants and personnel were not blinded). Quality of evidence was downgraded by one level.<br/> <sup>f</sup>An improvement in TcPO₂ reading might not correlate with an improvement in clinical symptoms and functions. Quality of evidence was downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010747-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010747-sec-0044"></div> <section id="CD010747-sec-0045"> <h3 class="title" id="CD010747-sec-0045">Description of the condition</h3> <p>Peripheral arterial disease (PAD) affects 3% to 10% of the population (<a href="./references#CD010747-bbs2-0170" title="NorgrenL , HiattWR , DormandyJA , HirschAT , JaffMR , DiehmC , et al. The next 10 years in the management of peripheral artery disease: Perspectives from the 'PAD 2009' conference. European Journal of Vascular and Endovascular Surgery2010;40:375‐80. ">Norgren 2010</a>). It is a global health problem that is associated with significant morbidity and mortality attributed to intermittent claudication and critical limb ischaemia (CLI). Intermittent claudication is the most common presentation of PAD and is generally managed conservatively. Critical limb ischaemia, the severe form of PAD, is characterised by rest pain, ulceration, and gangrene. Revascularisation therapy via the surgical or endovascular approach is the gold standard treatment for severe PAD, provided with the aim of improving blood flow to the affected extremity. However, this treatment modality cannot be applied to over 30% of patients owing to excessive anaesthetic and operative risks and unfavourable vascular involvement (<a href="./references#CD010747-bbs2-0175" title="SasajimaT , KuboY , InabaM , GohK , AzumaN . Role of infrainguinal bypass in Buerger's disease: an eighteen‐year experience. European Journal of Vascular and Endovascular Surgery1997;13(2):186‐92. ">Sasajima 1997</a>). Moreover, revascularisation therapy is likely to be futile in the presence of extensive atherosclerotic plaque and low rates of long‐term vessel patency in severe PAD (<a href="./references#CD010747-bbs2-0147" title="ConradMF , CrawfordRS , HackneyLA , ParuchuriV , AbularrageCJ , PatelVI , et al. Endovascular management of patients with critical limb ischemia. Journal of Vascular Surgery2011;53(4):1020‐5. ">Conrad 2011</a>). Hence, many patients are reliant on medical therapy that may halt disease progression only temporarily, leaving limb amputation as the only remaining option for relief from pain or gangrene (<a href="./references#CD010747-bbs2-0146" title="BottiC , MaioneC , CoppolaA , SicaV , CobellisG . Autologous bone marrow cell therapy for peripheral arterial disease. Stem Cells and Cloning: Advances and Applications2012;5:5‐14. ">Botti 2012</a>). Of note, after one year from diagnosis, limb amputation is unavoidable in 30% of patients with CLI (<a href="./references#CD010747-bbs2-0169" title="NorgrenL , HiattWR , DormandyJA , NehlerMR , HarrisKA , FowkesFG , TASC II Working Group. Inter‐society consensus for the management of peripheral arterial disease (TASC II). Journal of Vascular Surgery2007;45(Suppl S):S5‐67. ">Norgren 2007</a>). An estimated 120 to 150 amputations are performed per million people per year, and one‐quarter of these patients require long‐term institutional care or professional assistance at home (<a href="./references#CD010747-bbs2-0169" title="NorgrenL , HiattWR , DormandyJA , NehlerMR , HarrisKA , FowkesFG , TASC II Working Group. Inter‐society consensus for the management of peripheral arterial disease (TASC II). Journal of Vascular Surgery2007;45(Suppl S):S5‐67. ">Norgren 2007</a>). There is a critical need to develop novel strategies to promote vascular regeneration or neovascularisation in patients with CLI who are not suitable for conventional treatments, to reduce physical disability, mortality, and socioeconomic burden. </p> </section> <section id="CD010747-sec-0046"> <h3 class="title" id="CD010747-sec-0046">Description of the intervention</h3> <p>Although initial clinical studies on cell‐based therapy have been encouraging, current evidence from large‐scale randomised controlled clinical trials (RCTs) comparing active treatment versus placebo is limited, leading to a previous Cochrane review concluding that there was "insufficient evidence to support cell therapy in clinical practice" (<a href="./references#CD010747-bbs2-0167" title="MoazzamiK , MoazzamiB , RoohiA , NedjatS , DolmatovaE . Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD008347.pub3] ">Moazzami 2014</a>). </p> <p>To date, the types of cell‐based products used for implantation in CLI patients have been derived from bone marrow‐mononuclear cells (BM‐MNCs) (<a href="./references#CD010747-bbs2-0151" title="DurduS , AkarAR , AratM , SancakT , ErenNT , OzyurdaU . Autologous bone‐marrow mononuclear cell implantation for patients with Rutherford grade II‐III thromboangiitis obliterans. Journal of Vascular Surgery2006;44(4):732‐9. ">Durdu 2006</a>; <a href="./references#CD010747-bbs2-0166" title="MiyamotoK , NishigamiK , NagayaN , AkutsuK , ChikuM , KameiM , et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation2006;114(24):2679‐84. ">Miyamoto 2006</a>; <a href="./references#CD010747-bbs2-0116" title="Tateishi‐YuyamaE , MatsubaraH , MuroharaT , IkedaU , ShintaniS , MasakiH , et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone‐marrow cells: a pilot study and a randomised controlled trial. Lancet2002;360(9331):427‐35. [PUBMED: 12241713] ">Tateishi‐Yuyama 2002</a>), peripheral blood‐mononuclear cells (PB‐MNCs) (<a href="./references#CD010747-bbs2-0158" title="HuangPP , LiSZ , HanMZ , XiaoZJ , YangRC , QuiLG , et al. Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. Thrombosis and Haemostasis2004;91(3):606‐9. ">Huang 2004</a>; <a href="./references#CD010747-bbs2-0162" title="KawamuraA , HorieT , TsudaI , AbeY , YamadaM , EgawaH , et al. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. Journal of Artificial Organs2006;9(4):226‐33. ">Kawamura 2006</a>; <a href="./references#CD010747-bbs2-0066" title="LenkK , AdamsV , LurzP , ErbsS , LinkeA , GielenS , et al. Therapeutical potential of blood‐derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. European Heart Journal2005;26(18):1903‐9. [PUBMED: 15855189] ">Lenk 2005</a>; <a href="./references#CD010747-bbs2-0074" title="MatsuiK , MurakamiY , YoshiokaT , MuroiK , KasudaH , ShimpoM , et al. Therapeutic angiogenesis by transplantation of autologous bone marrow and peripheral blood mononuclear cells in patients with peripheral arterial disease. International Journal of Angiology2003;12:155–61. ">Matsui 2003</a>), granulocyte colony‐stimulating factor (G‐CSF)‐mobilised PB‐MNCs (mPBSCs) (<a href="./references#CD010747-bbs2-0051" title="HuangP , LiS , HanM , XiaoZ , YangR , HanZC . Autologous transplantation of granulocyte colony‐stimulating factor‐mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care2005;28(9):2155‐60. [PUBMED: 16123483] NCT00730561 . Hematopoietic stem cell transplantation for the treatment of limb ischemia and diabetic neuropathy. clinicaltrials.gov/ct2/show/NCT00730561 (first received 8 August 2008). ">Huang 2005</a>; <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0054" title="IshidaA , OhyaY , SakudaH , OhshiroK , HigashiuesatoY , NakaemaM , et al. Autologous peripheral blood mononuclear cell implantation for patients with peripheral arterial disease improves limb ischemia. Circulation Journal2005;69(10):1260‐5. [PUBMED: 16195628] ">Ishida 2005</a>), CD34 antigen‐positive mononuclear cells (MNCs) (<a href="./references#CD010747-bbs2-0159" title="InabaS , EgashiraK , KomoriK . Peripheral‐blood or bone‐marrow mononuclear cells for therapeutic angiogenesis?. Lancet2002;360(9350):2083. ">Inaba 2002</a>; <a href="./references#CD010747-bbs2-0057" title="KawamotoA , KatayamaM , HandaN , KinoshitaM , TakanoH , HoriiM , et al. Intramuscular transplantation of G‐CSF‐mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single‐blinded, dose‐escalation clinical trial. Stem Cells2009;27(11):2857‐64. [PUBMED: 19711453] ">Kawamoto 2009</a>), CD133 antigen‐positive MNCs (<a href="./references#CD010747-bbs2-0018" title="BurtRK , TestoriA , OyamaY , RodriguezHE , YaungK , VillaM , et al. Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplantation2010;45(1):111‐6. [PUBMED: 19448678] ">Burt 2010</a>), and BM‐mesenchymal stem cells (BM‐MSCs) (<a href="./references#CD010747-bbs2-0026" title="DashNR , DashSN , RoutrayP , MohapatraS , MohapatraPC . Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow‐derived mesenchymal stem cells. Rejuvenation Research2009;12(5):359‐66. [PUBMED: 19929258] ">Dash 2009</a>; <a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> <p>Cell implantation procedures are generally safe and well tolerated, as has been described in extensive clinical studies involving patients with PAD that utilised stem cells derived from various sources (<a href="./references#CD010747-bbs2-0145" title="BenoitE , O'DonnellTF , PatelAN . Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review. Cell Transplantation2013;22(3):545‐62. ">Benoit 2013</a>; <a href="./references#CD010747-bbs2-0163" title="LiewA , BhattacharyaV , ShawJ , StansbyG . Cell therapy for critical limb ischemia: a meta‐analysis of randomized controlled trials. Angiology2016;67(5):444‐555. [PUBMED: 26195561] ">Liew 2016</a>; <a href="./references#CD010747-bbs2-0165" title="LiuY , XuY , FangF , ZhangJ , GuoL , WengZ . Therapeutic efficacy of stem cell‐based therapy in peripheral arterial disease: a meta‐analysis. PloS One2015;10(4):e0125032. [PUBMED: 25923119] ">Liu 2015</a>; <a href="./references#CD010747-bbs2-0180" title="SunX , YingJ , WangY , LiW , WuY , YaoB , et al. Meta‐analysis on autologous stem cell transplantation in the treatment of limb ischemia. International Journal of Clinical and Experimental Medicine2015;8(6):8740‐8. [PUBMED: 26309525] ">Sun 2015</a>). Bone marrow is the most common source of stem cells in clinical trials involving cell‐based therapy. However, mobilised stem cells from patients' peripheral blood after administration of G‐CSF (mPBSCs) are now preferred over bone marrow stem cells owing to relative ease of collection and avoidance of anaesthesia and pain associated with bone marrow biopsy (<a href="./references#CD010747-bbs2-0152" title="FadilahSA , Mohd‐RazifMI , SeeryZA , Nor‐RafeahT , Wan‐FarizaWJ , HabsahA , et al. Predictors of the yield of mobilized peripheral blood CD34+ cells in HLA‐matched sibling donor. Transfusion and Apheresis Science2013;49(3):583‐9. [PUBMED: 24012241] ">Fadilah 2013</a>). Apart from bone marrow and peripheral blood, mesenchymal stem cells (MSCs) can be isolated from various adult human tissues (e.g. adipose tissue, skeletal muscles, tendons, nerves, cartilages) or neonatal tissues (placenta and umbilical cord blood). The safety and efficacy of MSCs isolated from adipose tissue (AT‐MSCs) in a small series of CLI patients have been reported (<a href="./references#CD010747-bbs2-0065" title="LeeHC , AnSG , LeeHW , ParkJS , ChaKS , HongTJ , et al. Safety and effect of adipose tissue‐derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circulation Journal2012;76(7):1750‐60. [PUBMED: 22498564] ">Lee 2012</a>). However, apart from bone marrow, peripheral blood, and adipose tissue sources, MSCs derived from other human tissues have not been tested in CLI patients. </p> <p>Mononuclear cells and stem cells derived from different sources may lead to different clinical outcomes in patients with PAD. Stem cells obtained from different sources may vary in biological (plasticity, self‐renewal, differentiation, homing, migration, secretion of trophic factors) and immunological (modulation of immune response) properties. This may be attributed to the inherent biological properties of the stem cells or to changes to the cells that may occur during cell enrichment and culture. For example, G‐CSF injection used to mobilise bone marrow‐derived progenitor cells may significantly enhance the formation of several growth factors involved in vascular repair (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>). In addition, the apheresis procedure results in transient cleavage of chemokine receptors expressed on cell surfaces, causing uncoupling from the bone marrow stroma (<a href="./references#CD010747-bbs2-0157" title="HonoldJ , LehmannR , HeeschenC , WalterDH , AssmusB , SasakiK , et al. Effects of granulocyte colony stimulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arteriosclerosis Thrombosis and Vascular Biology2006;26(10):2238‐43. ">Honold 2006</a>). Implantation of cells into the lower limb of CLI patients can be performed via several routes including intramuscular, intra‐arterial, or a combination of both, although it is yet unclear which method is superior (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>). Intramuscular administration is usually performed through multiple injections at the level of gastrocnemius muscles, and intra‐arterial infusion is usually performed via the femoral artery. Limited data from two RCTs have not shown superiority of either route (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>). </p> </section> <section id="CD010747-sec-0047"> <h3 class="title" id="CD010747-sec-0047">How the intervention might work</h3> <p>To date, the mechanisms by which implanted cells improve clinical outcomes in patients with PAD are still unclear. Experimental animal studies indicate that bone marrow‐derived cells contribute to vascular and muscle regeneration by physically integrating into the tissues, by secreting growth factors, or by both means (<a href="./references#CD010747-bbs2-0153" title="FadiniGP , AgostiniC , SartoreS , AvogaroA . Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis2007;194(1):46‐54. ">Fadini 2007</a>; <a href="./references#CD010747-bbs2-0157" title="HonoldJ , LehmannR , HeeschenC , WalterDH , AssmusB , SasakiK , et al. Effects of granulocyte colony stimulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arteriosclerosis Thrombosis and Vascular Biology2006;26(10):2238‐43. ">Honold 2006</a>). Adult bone marrow stem cells with angiogenic potential such as endothelial progenitor cells (EPCs) and MSCs have the capability to stimulate formation of new blood vessels by differentiating into endothelial cells and vascular smooth muscle (<a href="./references#CD010747-bbs2-0176" title="SchattemanGC , AwadO . Hemangioblasts, angioblasts, and adult endothelial cell progenitors. The Anatomical Record Part A. Discoveries in Molecular, Cellular, and Evolutionary Biology2004;276(1):13‐21. ">Schatteman 2004</a>), and by stimulating endothelial cell proliferation and migration (<a href="./references#CD010747-bbs2-0171" title="PittengerMF , MackayAM , BeckSC , JaiswalRK , DouglasR , MoscaJD , et al. Multilineage potential of adult human mesenchymal stem cells. Science1999;284(5411):143‐7. ">Pittenger 1999</a>; <a href="./references#CD010747-bbs2-0174" title="ReyesM , DudekA , JahagirdarB , KoodieL , MarkerPH , VerfaillieCM . Origin of endothelial progenitors in human postnatal bone marrow. Journal of Clinical Investigation2002;109(3):337‐46. ">Reyes 2002</a>). EPCs also exert direct angiogenic action through their ability to secrete paracrine mediators (<a href="./references#CD010747-bbs2-0160" title="JarajapuYP , GrantMB . The promise of cell‐based therapies for diabetic complications challenges and solutions. Circulation Research2010;106(5):854‐69. ">Jarajapu 2010</a>). Furthermore, MSCs support neo‐angiogenesis by releasing soluble factors to stimulate EPC sprouting from pre‐existing blood vessels (<a href="./references#CD010747-bbs2-0023" title="CobellisG , BottiC , TaddeoA , SilvestroniA , LilloS , DaPonteA , et al. Successful bone marrow transplantation reveals the lack of endothelial progenitor cells mobilization in a patient with critical limb ischemia: a case report. Transplantation Proceedings2010;42(7):2816‐20. [PUBMED: 20832596] ">Cobellis 2010</a>; <a href="./references#CD010747-bbs2-0160" title="JarajapuYP , GrantMB . The promise of cell‐based therapies for diabetic complications challenges and solutions. Circulation Research2010;106(5):854‐69. ">Jarajapu 2010</a>). Therefore, cell implantation into ischaemic limbs may promote neo‐angiogenesis by providing precursor cells capable of vascular transdifferentiation, and by supplying multiple angiogenic cytokines, growth factors, and homing signals for mural cells or pericytes for microvascular stabilisation (<a href="./references#CD010747-bbs2-0145" title="BenoitE , O'DonnellTF , PatelAN . Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review. Cell Transplantation2013;22(3):545‐62. ">Benoit 2013</a>; <a href="./references#CD010747-bbs2-0161" title="KaelinWG , RatcliffePJ . Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Molecular Cell2008;30(4):393‐402. ">Kaelin 2008</a>). The combination of these mechanisms is responsible for augmenting vascular repair and ameliorating tissue perfusion, leading to reversal of ischaemia in the affected limb. </p> </section> <section id="CD010747-sec-0048"> <h3 class="title" id="CD010747-sec-0048">Why it is important to do this review</h3> <p>It is important to determine if different sources or methods of MNCs and stem cell preparations have different effects on clinical outcomes following implantation into CLI patients; and whether a combination versus a single type of MNC or stem cell treatment improves ischaemic symptoms and survival among these patients. To date, data comparing the angiogenic potency of autologous cells derived from different sources are limited. Moreover, direct comparison of different autologous cell types shows conflicting results (<a href="./references#CD010747-bbs2-0163" title="LiewA , BhattacharyaV , ShawJ , StansbyG . Cell therapy for critical limb ischemia: a meta‐analysis of randomized controlled trials. Angiology2016;67(5):444‐555. [PUBMED: 26195561] ">Liew 2016</a>). One study showed that BM‐MNCs were associated with significant improvement in lower limb perfusion when compared to PB‐MNCs (<a href="./references#CD010747-bbs2-0116" title="Tateishi‐YuyamaE , MatsubaraH , MuroharaT , IkedaU , ShintaniS , MasakiH , et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone‐marrow cells: a pilot study and a randomised controlled trial. Lancet2002;360(9331):427‐35. [PUBMED: 12241713] ">Tateishi‐Yuyama 2002</a>); another study showed similar outcomes in both treatment groups (<a href="./references#CD010747-bbs2-0098" title="OnoderaR , TeramukaiS , TanakaS , KojimaS , HorieT , MatobaS , et al. Bone marrow mononuclear cells versus G‐CSF‐mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long‐term prognosis. Bone Marrow Transplantation2011;46(2):278‐84. [PUBMED: 20479708] ">Onodera 2011</a>). Additionally, other sources of stem cells such as placenta or stored autologous cord blood might become available. It is not yet known whether cells from these sources would be as effective as cells derived from bone marrow or peripheral blood for treating CLI patients. Furthermore, thus far no safety data have been published by head‐to‐head RCTs comparing a particular cell‐based therapy versus another type of cell‐based therapy. The individual RCTs comparing cell treatment and non‐cell treatment presented in previous reviews have not reported significant procedure‐related complications or adverse biochemical and immunological effects related to cell implantation in CLI patients (<a href="./references#CD010747-bbs2-0165" title="LiuY , XuY , FangF , ZhangJ , GuoL , WengZ . Therapeutic efficacy of stem cell‐based therapy in peripheral arterial disease: a meta‐analysis. PloS One2015;10(4):e0125032. [PUBMED: 25923119] ">Liu 2015</a>; <a href="./references#CD010747-bbs2-0181" title="TeraaM , SprengersRW , van derGraafY , PetersCE , MollFL , VerhaarMC . Autologous bone marrow‐derived cell therapy in patients with critical limb ischemia: a meta‐analysis of randomized controlled clinical trials. Annals of Surgery2013;258(6):922‐9. [PUBMED: 23426345] ">Teraa 2013</a>; <a href="./references#CD010747-bbs2-0121" title="WangX , JiangL , WangX , YinF , LiG , FengX , et al. Combination of autologous transplantation of G‐CSF‐mobilized peripheral blood mononuclear cells and Panax notoginseng saponins in the treatment of unreconstructable critical limb ischemia. Annals of Vascular Surgery2014;28(6):1501‐12. [PUBMED: 24632316] ">Wang 2014</a>). </p> <p>Up‐to‐date synthesised evidence on optimal cell sources, cell dose, and administration protocols for the treatment of 'no‐option' CLI patients is required to guide clinical practice and direct future research. The current proposed meta‐analysis aims to attain comprehensive insight into the optimal cell‐based treatment program for patients with CLI. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010747-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010747-sec-0049"></div> <p>To compare the efficacy and safety of autologous cells derived from different sources, prepared using different protocols, administered at different doses, and delivered via different routes for the treatment of 'no‐option' CLI patients. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010747-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010747-sec-0050"></div> <section id="CD010747-sec-0051"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010747-sec-0052"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs). We excluded cluster‐randomised trials (owing to difficulties in adjusting for the unit of analysis) and cross‐over studies (owing to a possible 'contaminating' effect of one intervention on another). </p> </section> <section id="CD010747-sec-0053"> <h4 class="title">Types of participants</h4> <p>Study participants were adult patients with the diagnosis of CLI who were not candidates for revascularisation therapy and did not show any improvement in response to best standard medical therapy. We included in the review all causes of CLI such as atherosclerosis, Buerger's disease, acute embolism, and others. We applied no age restriction. </p> </section> <section id="CD010747-sec-0054"> <h4 class="title">Types of interventions</h4> <p>Intervention: administration to CLI patients of autologous MNCs or stem cells obtained from a particular source, prepared using a particular protocol, administered at a particular dose, and delivered via a particular route. </p> <p>Comparison: administration to CLI patients of autologous MNCs or stem cells obtained from any other source of MNCs or stem cells, prepared using any other protocol, administered at any other dose, and delivered via any other route. </p> <p>We did not compare administration of autologous MNCs or stem cells to patients with CLI against no cell therapy, control, standard therapy, or best medical practice because this approach would overlap that used in another Cochrane review (<a href="./references#CD010747-bbs2-0167" title="MoazzamiK , MoazzamiB , RoohiA , NedjatS , DolmatovaE . Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD008347.pub3] ">Moazzami 2014</a>). </p> </section> <section id="CD010747-sec-0055"> <h4 class="title">Types of outcome measures</h4> <section id="CD010747-sec-0056"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010747-list-0001"> <li> <p>All‐cause mortality</p> </li> <li> <p>Amputation rate</p> </li> <li> <p>Wound/ulcer healing as determined by the number of ulcers healed and the change in ulcer size </p> </li> </ol> </p> </section> <section id="CD010747-sec-0057"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010747-list-0002"> <li> <p>Reduction in rest pain as assessed by a validated visual analogue scale (VAS) or analgesic requirement (rest pain score) </p> </li> <li> <p>Improvement in lower limb perfusion as measured by improvement in ankle‐brachial index (ABI) </p> </li> <li> <p>Improvement in lower limb perfusion as measured by improvement in transcutaneous oxygen tension (TcO₂) </p> </li> <li> <p>Improvement in ischaemic symptoms as assessed by improvement in pain‐free walking distance (PFWD) and pain‐free walking time (PFWT) </p> </li> <li> <p>Improvement in vascularity and blood supply to the ischaemic limb as measured by the numbers of newly formed collaterals in the lower limbs </p> </li> <li> <p>Adverse effects and safety</p> <ol id="CD010747-list-0003"> <li> <p>Adverse effects included an inflammatory reaction at the stem cell implantation site (grade I to IV), cardiovascular abnormalities, or thromboembolic complications </p> </li> <li> <p>Safety was measured as the rate of adverse events and the rate of withdrawal</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD010747-sec-0058"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010747-sec-0059"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist (CIS) first searched the following databases for relevant trials on 17 February 2017: the Cochrane Vascular Specialised Register; and the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1) in the Cochrane Library, via the Cochrane Register of Studies Online. See <a href="./appendices#CD010747-sec-0149">Appendix 1</a> for details of the search strategy used to search CENTRAL. </p> <p>The CIS also searched the following trials databases on 17 February 2017 for details of ongoing and unpublished studies using the terms "(critical ischemia or critical ischaemia)" and "cell": the World Health Organization International Clinical Trials Registry (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>); ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>); and the International Standard Randomized Controlled Trials Number (ISRCTN) Register (<a href="http://www.isrctn.com/" target="_blank">isrctn.com/</a>). </p> <p>The CIS performed a top‐up search of the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE Ovid, Embase Ovid, CINAHL, AMED, and trials registries, on 16 May 2018. See <a href="./appendices#CD010747-sec-0150">Appendix 2</a> for details of the search strategies used. </p> <section id="CD010747-sec-0060"> <h5 class="title">Review authors' searches</h5> <p>The review authors searched PubMed until February 2017 using the strategy shown in <a href="./appendices#CD010747-sec-0151">Appendix 3</a>. </p> </section> </section> <section id="CD010747-sec-0061"> <h4 class="title">Searching other resources</h4> <p>To identify further eligible studies, we inspected the reference lists of relevant articles that we had retrieved via the search strategies outlined above and from relevant Cochrane reviews that assessed cell‐based treatments as interventions. </p> </section> </section> <section id="CD010747-sec-0062"> <h3 class="title" id="CD010747-sec-0062">Data collection and analysis</h3> <section id="CD010747-sec-0063"> <h4 class="title">Selection of studies</h4> <p>Two review authors (NAI and MKAAH) independently screened the titles and abstracts of articles retrieved in the first round of the search, aiming to exclude articles that were clearly irrelevant. After completing the initial step of screening, we had obtained a list of articles that appeared to be relevant to our review. Two review authors (SFAW and NAM) independently assessed the short‐listed articles in greater detail by using the abstract and full text to identify eligible articles. In instances of disagreements between review authors on article selection, a third review author (NML) acted as an arbiter. </p> <p>We accepted published and unpublished studies in full article and abstract forms, as long as assessment of risk of bias was possible and relevant data were available. When required, we would contact authors of unpublished studies and studies available only as abstracts to request further information. </p> <p>We screened for duplicate publications of the same trial, and we contacted the trial authors for clarification when necessary. </p> </section> <section id="CD010747-sec-0064"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (SFAW, NAI, and MKAAH) independently extracted and coded all data for each included study using a proforma designed specifically for this review. We extracted the following information from each study: study design, participants, setting, sample size, nature of intervention, comparison, outcomes, methods (unit of allocation and analysis), and results. We screened for duplicate entry of patients, when possible, by matching the initial number of patients recruited against the total number along each step in the conduct of the study. If we discovered a discrepancy (e.g. if the total number in a later stage of the study exceeded the initial number), we attempted to look for an explanation within the article (e.g. multiple enrolment of the same patient at different hospital admissions). We contacted study authors for clarification if necessary. We compared data in duplicate publications against data from all versions to avoid duplicate extraction. </p> <p>We resolved disagreements among the review authors through discussion leading to a consensus. </p> </section> <section id="CD010747-sec-0065"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (NAI, SFAW, and NML) independently assessed each included study using Cochrane's tool for assessing risk of bias to address six specific domains (<a href="./references#CD010747-bbs2-0156" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p> <ol id="CD010747-list-0004"> <li> <p>Sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other issues (e.g. extreme baseline imbalance).</p> </li> </ol> </p> <p>We made a judgement on each of the criteria above as to whether the study was at high, low, or unclear risk of bias. We assessed blinding for each category of outcomes (objective and subjective) separately when possible. We completed a 'Risk of bias' table for each eligible study and resolved disagreement among review authors through discussion leading to a consensus. We presented an overall assessment of the risk of bias using the 'Risk of bias' graph and the 'Risk of bias' summary. </p> </section> <section id="CD010747-sec-0066"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data (amputation rate and ulcer healing rate, numbers of patients with improvement in blood flow parameters, and number of limbs with new collaterals), we used risk ratio (RR) to measure outcome estimates on the same scale. For continuous data (rest pain score, ABI score, TcO₂ reading, PFWD, PFWT), we pooled measures at a similar time point using mean difference (MD). If pooled analyses were not possible, we reported results of the studies individually. </p> </section> <section id="CD010747-sec-0067"> <h4 class="title">Unit of analysis issues</h4> <p>We used each individual patient as our unit of analysis when possible. However, some studies reported their results using the limbs as the unit of analysis without adjusting results to account for non‐independence between two limbs of the same patient. None of the studies reported the number of patients with one or two limbs included in the analysis, making it impossible for us to adjust the results. We therefore reported the results of those studies unadjusted but undertook a sensitivity analysis when we encountered a mixture of studies with patients and limbs as the unit of analysis, to assess the impact of pooled results after exclusion of studies that reported results using the limbs as the unit of analysis. </p> <p>We did not include cluster‐RCTs and cross‐over studies.</p> </section> <section id="CD010747-sec-0068"> <h4 class="title">Dealing with missing data</h4> <p>We assessed the dropout rate of each study and determined whether an intention‐to‐treat analysis was performed. To assess whether the dropout rate was worrisome, we inspected event rates for intervention and comparison groups. We then used a 'worst‐case scenario' method for the primary outcomes (<a href="./references#CD010747-bbs2-0155" title="GuyattGH , SackettDL , CookDJ . Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence‐Based Medicine Working Group. JAMA1993;270(21):2598‐601. ">Guyatt 1993</a>). For instance, with negatively worded outcomes (such as mortality), for a trial that favoured the intervention group we assumed that all dropouts from the intervention group had developed the outcome, and that all dropouts from the comparison group had not developed the outcome. We then analysed the results to see if such an assumption changed the direction of the results (e.g. from favouring the intervention group to favouring the comparison group). If so, we considered the dropout rate to be worrisome and made a corresponding note in the table that corresponded to characteristics of the study and its accompanying risk of bias assessment table under the heading of 'Incomplete outcome data'. We made the reverse assumption when a trial favoured the comparison group. </p> </section> <section id="CD010747-sec-0069"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed all included studies in terms of their clinical and methodological characteristics, including the following. </p> <p> <ol id="CD010747-list-0005"> <li> <p>Aetiology of the disease.</p> </li> <li> <p>Baseline characteristics of participants (age, gender, race and ethnicity, comorbidity group). </p> </li> <li> <p>Nature of the intervention (different regimens of implantation, different types of cells, different preparations and doses of cells implanted). </p> </li> <li> <p>Types of co‐interventions.</p> </li> <li> <p>Duration of follow‐up period.</p> </li> <li> <p>Methodological quality (as detailed in the assessment of risk of bias section, e.g. studies at high risk of bias, which were defined as studies with unclear or no allocation concealment; studies in which participants, caregivers, or investigators were not blinded, or in which blinding was unclear). </p> </li> </ol> </p> <p>We visually inspected the forest plots for any evidence of heterogeneity of treatment effects. We used the I² statistic to measure inconsistency in results (<a href="./references#CD010747-bbs2-0148" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) . Chapter 9. Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>), with a value greater than 50% indicating substantial statistical heterogeneity. If we found significant statistical heterogeneity but considered the studies suitable for a meta‐analysis based on clinical and methodological characteristics, we then used the random‐effects model to provide the pooled effect estimates. </p> </section> <section id="CD010747-sec-0070"> <h4 class="title">Assessment of reporting biases</h4> <p>We specifically assessed publication bias in our review using a funnel plot if 10 or more studies were included in the analysis. If publication bias was implied by significant asymmetry of the funnel plot, we would have included a statement in our results with a corresponding note of caution in our discussion. </p> </section> <section id="CD010747-sec-0071"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager to perform meta‐analysis of the included studies (<a href="./references#CD010747-bbs2-0173" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 5.3</a>). We used a fixed‐effect model unless we found significant heterogeneity, in which case we employed the strategies as outlined in the previous section on assessment of heterogeneity. For data management, we followed the strategies detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010747-bbs2-0156" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Our primary data analyses followed the intention‐to‐treat principle, namely, we used the original number of participants allocated to each study arm as the denominator in subsequent analyses. </p> </section> <section id="CD010747-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Had sufficient data been available, we would have performed the following subgroup analyses for studies describing patients: </p> <p> <ol id="CD010747-list-0006"> <li> <p>with different severity of CLI (e.g. rest pain vs tissue loss);</p> </li> <li> <p>with different aetiology of CLI (e.g. atherosclerosis obliterans (ASO) vs thromboangiitis obliterans (TAO)); </p> </li> <li> <p>with and without significant comorbidity (e.g. smoking, diabetes, hypercholesterolaemia, hypertension); </p> </li> <li> <p>with different age groups;</p> </li> <li> <p>with different genders;</p> </li> <li> <p>with different races or ethnicities;</p> </li> <li> <p>injected with cells obtained via different preparation techniques (e.g. fresh vs cultured, non‐selected vs selected); </p> </li> <li> <p>injected with different doses of cells;</p> </li> <li> <p>injected with single versus a combination of cell‐based products; and</p> </li> <li> <p>implanted via different routes;</p> </li> </ol> </p> <p>or when:</p> <p> <ol id="CD010747-list-0007"> <li> <p>the intervention was administered with and without co‐intervention; or</p> </li> <li> <p>studies were undertaken in patients with different follow‐up periods.</p> </li> </ol> </p> </section> <section id="CD010747-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analysis for each outcome that we extracted and pooled from a mixture of studies with patients and limbs as the unit of analysis to assess the impact of the pooled results after exclusion of studies that reported results using the limbs as the unit of analysis. </p> <p>Had sufficient data been available, we would have performed the following additional sensitivity analyses to assess the impact of excluding studies based on the following criteria. </p> <p> <ol id="CD010747-list-0008"> <li> <p>Significant or worrisome dropout rates, as defined under the heading <a href="#CD010747-sec-0068">Dealing with missing data</a>. </p> </li> <li> <p>Significant methodological issues identified in the assessment of risk of bias. For the purpose of this systematic review, we took the following criteria to indicate a significant risk of bias: studies with unclear or no allocation concealment; and studies in which participants, caregivers, or investigators were not blinded, or in which blinding was unclear. </p> </li> </ol> </p> <section id="CD010747-sec-0074"> <h5 class="title">'Summary of findings'</h5> <p>We presented in 'Summary of findings' (SoF) tables the main findings of this review concerning quality of evidence, magnitude of effects of the interventions examined, and sum of available data on the primary outcomes in the review, namely, all‐cause mortality, amputation rate, and wound/ulcer healing, as well as the major secondary outcomes (i.e. reduction in rest pain and improvement in lower limb perfusion as measured by ABI and TcO₂) (<a href="./references#CD010747-bbs2-0177" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12. Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>), according to <a href="./references#CD010747-bbs2-0156" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>. We used the web‐based GRADEpro software (gdt.guidelinedevelopment.org) to generate the SoF table (<a href="./references#CD010747-bbs2-0178" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH , on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 11. Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011a</a>). In generating the SoF table, we took the median control group event rate for the outcome as showing 'moderate risk'. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010747-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010747-sec-0075"></div> <section id="CD010747-sec-0076"> <h3 class="title">Description of studies</h3> <p>A summary of our search results is shown in <a href="#CD010747-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010747-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010747-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <section id="CD010747-sec-0077"> <h4 class="title">Results of the search</h4> <p>We included in this review seven RCTs from eight published articles (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>; <a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>; <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>). We excluded 124 studies (141 reports) on the basis of study design, characteristics of participants, types of interventions, characteristics of cell treatment, and absence of outcome data (see <a href="./references#CD010747-sec-0161" title="">Characteristics of excluded studies</a>). We identified six studies (seven reports) awaiting classification (<a href="./references#CD010747-bbs2-0132" title="Gurunathan ManiS , RajuR , Kuppu SampathV . Multicentre randomised clinical trial on the role of autologous bone‐marrow aspirate‐concentrate (BMAC)/CD34/(EPC) in non‐reconstructable critically ischaemic limbs. The Vascular Society of Great Britain &amp; Ireland Yearbook 2009. 2009:56. ">Gurunathan 2009</a>; <a href="./references#CD010747-bbs2-0133" title="KorymasovEA , TiuminaOV , AiupovAM , KazantsevAV , RossievVA , MikheevGV , et al. Use of autologous progenitor cells of the bone marrow in treatment of patients with lower‐limb atherosclerosis obliterans. Angiologiia i Sosudistaia Khirurgiia = Angiology and Vascular Surgery2009;15(3):28‐31. [PUBMED: 20092179] ">Korymasov 2009</a>; <a href="./references#CD010747-bbs2-0134" title="MolaviB , ZafarghandiMR , AminizadehE , HosseiniSE , MirzayiH , ArabL , et al. Safety and efficacy of repeated bone marrow mononuclear cell therapy in patients with critical limb ischemia in a pilot randomized controlled trial. Archives of Iranian Medicine2016;19(6):388‐96. [PUBMED: 27293053] NCT01480414 . Side effects of 4 times bone marrow mononuclear transplantation in patients with ischemic lower limb. clinicaltrials.gov/ct2/show/NCT01480414 (first received 28 November 2011). ">Molavi 2016</a>; <a href="./references#CD010747-bbs2-0135" title="NCT00595257 . Feasibility study of autologous bone marrow aspirate concentrate for treatment of CLI. clinicaltrials.gov/ct2/show/study/NCT00595257 (first received 16 January 2008). ">NCT00595257</a>; <a href="./references#CD010747-bbs2-0136" title="NCT00987363 . Intraarterial infusion of autologous bone marrow in diabetic patients with chronic ischemia of lower limbs (CLI) no revascularization. clinicaltrials.gov/ct2/show/study/NCT00987363 (first recieved 30 September 2009). ">NCT00987363</a>; <a href="./references#CD010747-bbs2-0137" title="NCT02993809 . Autologous transplantation of BM‐ECs with platelet‐rich plasma extract for the treatment of critical limb ischemia. clinicaltrials.gov/ct2/show/study/NCT02993809 (first received 15 December 2016). ">NCT02993809</a>): three studies are clinical trial protocols without outcome data (<a href="./references#CD010747-bbs2-0135" title="NCT00595257 . Feasibility study of autologous bone marrow aspirate concentrate for treatment of CLI. clinicaltrials.gov/ct2/show/study/NCT00595257 (first received 16 January 2008). ">NCT00595257</a>; <a href="./references#CD010747-bbs2-0136" title="NCT00987363 . Intraarterial infusion of autologous bone marrow in diabetic patients with chronic ischemia of lower limbs (CLI) no revascularization. clinicaltrials.gov/ct2/show/study/NCT00987363 (first recieved 30 September 2009). ">NCT00987363</a>; <a href="./references#CD010747-bbs2-0137" title="NCT02993809 . Autologous transplantation of BM‐ECs with platelet‐rich plasma extract for the treatment of critical limb ischemia. clinicaltrials.gov/ct2/show/study/NCT02993809 (first received 15 December 2016). ">NCT02993809</a>), one pilot study provided preliminary reporting of outcome data based on small sample size (<a href="./references#CD010747-bbs2-0134" title="MolaviB , ZafarghandiMR , AminizadehE , HosseiniSE , MirzayiH , ArabL , et al. Safety and efficacy of repeated bone marrow mononuclear cell therapy in patients with critical limb ischemia in a pilot randomized controlled trial. Archives of Iranian Medicine2016;19(6):388‐96. [PUBMED: 27293053] NCT01480414 . Side effects of 4 times bone marrow mononuclear transplantation in patients with ischemic lower limb. clinicaltrials.gov/ct2/show/NCT01480414 (first received 28 November 2011). ">Molavi 2016</a>), one article provided incomplete reporting of outcome data (<a href="./references#CD010747-bbs2-0132" title="Gurunathan ManiS , RajuR , Kuppu SampathV . Multicentre randomised clinical trial on the role of autologous bone‐marrow aspirate‐concentrate (BMAC)/CD34/(EPC) in non‐reconstructable critically ischaemic limbs. The Vascular Society of Great Britain &amp; Ireland Yearbook 2009. 2009:56. ">Gurunathan 2009</a>), and one article written in the Russian language could not be assessed fully by the time of writing the review, and we are still awaiting its translated full‐text version (<a href="./references#CD010747-bbs2-0133" title="KorymasovEA , TiuminaOV , AiupovAM , KazantsevAV , RossievVA , MikheevGV , et al. Use of autologous progenitor cells of the bone marrow in treatment of patients with lower‐limb atherosclerosis obliterans. Angiologiia i Sosudistaia Khirurgiia = Angiology and Vascular Surgery2009;15(3):28‐31. [PUBMED: 20092179] ">Korymasov 2009</a>). (See <a href="./references#CD010747-sec-0162" title="">Characteristics of studies awaiting classification</a>.) We identified seven ongoing studies (seven reports) (<a href="./references#CD010747-bbs2-0138" title="NCT00311805 . Autologous CD34+ stem cell injection for severe intermittent claudication (leg pain). clinicaltrials.gov/ct2/show/study/NCT00311805 (first received 6 April 2006). ">NCT00311805</a>; <a href="./references#CD010747-bbs2-0139" title="NCT00753025 . Autologous bone marrow for lower extremity ischemia treating. clinicaltrials.gov/ct2/show/study/NCT00753025 (first received 16 September 2008). ">NCT00753025</a>; <a href="./references#CD010747-bbs2-0140" title="NCT01257776 . Human adipose derived mesenchymal stem cells for critical limb ischemia (CLI) in diabetic patients. clinicaltrials.gov/ct2/show/study/NCT01257776 (first received 10 December 2010). ">NCT01257776</a>; <a href="./references#CD010747-bbs2-0141" title="NCT01408381 . Intra‐arterial infusion of autologous bone marrow mononuclear cells in non‐diabetic patients with critical limb ischemia (CLI). clinicaltrials.gov/ct2/show/study/NCT01408381 (first received 3 August 2011). ">NCT01408381</a>; <a href="./references#CD010747-bbs2-0142" title="NCT01446055 . Safety and efficacy study of autologous BM‐MNC processed by two methods for treating patients with chronic limb ischemia. clinicaltrials.gov/ct2/show/study/NCT01446055 (first received 4 October 2011). ">NCT01446055</a>; <a href="./references#CD010747-bbs2-0143" title="NCT01745744 . Application of cell regeneration therapy with mesenchymal stem cells from adipose tissue in critical chronic ischemic syndrome of lower limbs (CLI) in nondiabetic patients. clinicaltrials.gov/ct2/show/study/NCT01745744 (first received 10 December 2012). ">NCT01745744</a>; <a href="./references#CD010747-bbs2-0144" title="NCT02454231 . Monocentric trial: stem cell emergency life threatening limbs arteriopathy (SCELTA). clinicaltrials.gov/ct2/show/NCT02454231 (first received 27 May 2015). ">NCT02454231</a>. (See <a href="./references#CD010747-sec-0163" title="">Characteristics of ongoing studies</a>.) Recent review articles and meta‐analyses did not yield additional relevant clinical trials. We did not identify new trials by scanning the reference lists of included clinical trials. </p> </section> <section id="CD010747-sec-0078"> <h4 class="title">Included studies</h4> <section id="CD010747-sec-0079"> <h5 class="title">Characteristics of included studies</h5> <p>We included seven RCTs that were conducted in four countries, including China (four studies), USA, Netherlands, and Slovakia (one study each). Six studies were single‐centre RCTs, and one was a multi‐centre RCT (see <a href="./references#CD010747-sec-0160" title="">Characteristics of included studies</a>). </p> </section> <section id="CD010747-sec-0080"> <h5 class="title">Characteristics of participants</h5> <p>The included studies were conducted between 2003 and 2010 and enrolled a total of 359 participants. The number of participants recruited in the individual RCTs ranged from 16 in <a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a> to 150 in <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>. The mean age of participants ranged from 61.8 years to 69.8 years. Atherosclerosis obliterans and thromboangiitis obliterans were the two most common aetiologies of CLI. Most studies reported the baseline demographics of participants, including age and gender, comorbidities (diabetes mellitus, renal failure, cerebral and coronary artery disease), and severity of limb ischaemia as comparable between groups. One study recruited only diabetic patients (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). In two studies, researchers used each of the two limbs as one experimental arm, resulting in administration of the two interventions to two different limbs of the same patient (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). Median follow‐up ranged from one to twelve months after cell implantation. </p> </section> <section id="CD010747-sec-0081"> <h5 class="title">Characteristics of cell treatment</h5> <p>The included RCTs used essentially two sources of autologous stem cells: bone marrow and peripheral blood. Five of the seven included RCTs used mononuclear cells (MNCs) harvested and separated manually from bone marrow by density gradient centrifugation on Ficoll‐Hypaque and implanted into affected limbs without prior manipulation; study authors denoted these as BM‐MNCs. Three RCTs used progenitor cells isolated from patients' peripheral blood via leukapheresis following administration of 5 μg/kg/d of G‐CSF for four or five days (termed 'mobilised PBSCs', or 'mPBSCs') for implantation (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>; <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>). One RCT further enriched the leukapheresis product (mPBSC) for CD34+ cells using a magnetic cell selection system before implantation of CD34+ cells (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). Bone marrow cells were cultured to generate mesenchymal stem cells (MSCs), and one RCT used these cells (BM‐MSCs) (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> <p>One RCT evaluated the effect of cell dose on clinical outcomes. In this study, researchers randomised patients and treated them with 1 × 10⁶ (high dose) and 1 × 10⁵ (low dose) autologous CD34+ cells/kg (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). No standard definition of high versus low cell dose is provided in the literature. However, we considered a standard definition not critical for determining clinical outcomes in the present review because only a single RCT performed this comparison, and pooled analysis was not feasible. </p> <p>Intramuscular (IM) cell implantation was the route most commonly employed. Other methods of cell administration were intra‐arterial (IA) ‐ in <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a> ‐ and combined IM plus IA ‐ in <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>. IM cell implantation was usually performed via multiple injections into the gastrocnemius muscle, and IA cell infusion was usually done through the femoral artery of the affected lower limb. </p> <p>Trials provided four major categories of interventions.</p> <p> <ol id="CD010747-list-0009"> <li> <p>Comparison between BM‐MNCs (104 participants) and mPBSCs (98 participants) in two RCTs (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>). </p> </li> <li> <p>Comparison between BM‐MNCs (20 participants) and BM‐MSCs (21 participants) in one RCT (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> </li> <li> <p>Comparison between high cell dose (9 participants) and low cell dose (7 participants) implanted into the affected limb in one RCT (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </li> <li> <p>Comparison between IM (52 participants) and IA or IA plus IM (48 participants) cell implantation in three RCTs (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>). </p> </li> </ol> </p> </section> <section id="CD010747-sec-0082"> <h5 class="title">Assessment of outcomes</h5> <p>For efficacy analysis, the participants in the seven included RCTs were pooled in groups according to source, type, dose, and route of delivery of MNCs/stem cells. We extracted the outcome data from individual RCTs and incorporated them into the meta‐analysis according to the following groups: BM‐MNCs versus mPBSCs, BM‐MNCs versus BM‐MSCs, high cell dose versus low cell dose, and IM implantation route versus IA infusion route. </p> <p>Most included RCTs assessed four efficacy outcomes almost exclusively, including amputation rate (six studies), rest pain (six studies), ulcer healing (three studies), and ABI (six studies). </p> <p>All RCTs assessed subjective symptoms (rest pain) and objective surrogate indexes of blood flow in the lower limbs (wound healing, ABI, TcO₂, PFWD, PFWT) before cell implantation and regularly thereafter, ranging from two weeks to twelve months. The researchers determined the number and nature of amputations at the end of the study. They determined wound or ulcer healing weekly by (1) ulcer healing rate (number of participants whose ulcers healed divided by the total number of participants with ulcers in a particular group) and (2) changes from baseline in ulcer size and area as measured by grid maps, acetate tracings, and digital planimetry. Trialists assessed rest pain using two types of numerical rating pain scales ranging from 0 (completely resolved without analgesics) to 4 points (severe pain unresolved with analgesics) (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>), or from 1 (least pain) to 10 points (greatest pain) on a visual analogue scale (VAS). They measured resting ABI using a laser Doppler at room temperature according to standard protocol. Study authors measured TcO₂ with a TCM400 Mk2 monitor (<a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>), and they assessed walking capacity reflected by a change in walking distance (metres), walking duration (minutes), and walking speed (miles per hour or mph) at a constant speed on a treadmill, or at the same ground with no inclination. Investigators determined collateral vessel formation of the lower limbs using magnetic resonance angiography (MRA) (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>), or via subtraction angiography (<a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>), before and at three to six months after cell implantation. They assessed angiographic scores of blood vessel images as +0 (no collateral formation), +2 (moderate collateral circulation), and +3 (abundant collateral circulation) (<a href="./references#CD010747-bbs2-0150" title="DrescherR , HallerS , KosterO , vonRothenburgT , TitschertA . Standard‐protocol moving‐table magnetic resonance angiography for planning of interventional procedures in patients with peripheral vascular occlusive disease. Clinical Imaging2006;30(6):382‐7. [PUBMED: 17101406] ">Drescher 2006</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>). They paid specific attention to detecting potential adverse effects resulting from cell harvesting and implantation during follow‐up visits. </p> </section> </section> <section id="CD010747-sec-0083"> <h4 class="title">Excluded studies</h4> <p>In total, we excluded 141 reports of 124 studies on the basis of study design, patient characteristics, types of interventions, characteristics of cell treatment, and incomplete outcome data (see <a href="./references#CD010747-sec-0161" title="">Characteristics of excluded studies</a>). </p> <p> <ol id="CD010747-list-0010"> <li> <p>Forty RCTs investigated effects of cell‐based treatment versus standard medical therapy (SMT), including BM‐MNCs versus SMT (<a href="./references#CD010747-bbs2-0009" title="AmannB , LudemannC , RuckertR , LawallH , LiesenfeldB , SchneiderM , et al. Design and rationale of a randomized, double‐blind, placebo‐controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT‐CLI). VASA. Zeitschrift fur Gefasskrankheiten2008;37(4):319‐25. [PUBMED: 19003741] ">Amann 2008</a>; <a href="./references#CD010747-bbs2-0011" title="AraiM , MisaoY , NagaiH , KawasakiM , NagashimaK , SuzukiK , et al. Granulocyte colony‐stimulating factor: a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circulation Journal2006;70(9):1093‐8. [PUBMED: 16936417] ">Arai 2006</a>; <a href="./references#CD010747-bbs2-0013" title="BarćP , SkóraJ , PupkaA , TurkiewiczD , DorobiszAT , GarcarekJ , et al. Bone‐marrow cells in therapy of critical limb ischaemia of lower extremities ‐ own experience. Acta Angiologica2006;12(4):155‐66. ">Barć 2006</a>; <a href="./references#CD010747-bbs2-0015" title="BenoitE , O'DonnellTFJr , IafratiMD , AsherE , BandykDF , HallettJW , et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. Journal of Translational Medicine2011;9:165. [PUBMED: 21951607] IafratiMD , HallettJW , GeilsG , PearlG , LumsdenA , PedenE , et al. Early results and lessons learned from a multicenter, randomized, double‐blind trial of bone marrow aspirate concentrate in critical limb ischemia. Journal of Vascular Surgery2011;54(6):1650‐8. [PUBMED: 22019148] ">Benoit 2011</a>; <a href="./references#CD010747-bbs2-0029" title="DouY , ZhaoJ , ZhangL , WangX , YuanH , YuanC . A follow‐up study on autologous bone marrow mononuclear cells transplantation for critical lower arteriosclerosis obliterans in diabetic patients. Zhongguo Xiu fu Chong Jian Wai ke za Zhi = Zhongguo Xiufu Chongjian Waike Zazhi = Chinese Journal of Reparative and Reconstructive Surgery2015;29(7):893‐8. [PUBMED: 26540987] ">Dou 2015</a>; <a href="./references#CD010747-bbs2-0041" title="GuY , GuoL , GuoJ , DardikA , ZhangS , TongZ , et al. Granulocyte colony‐stimulating factor improves the efficacy of autologous bone marrow‐derived mononuclear cell transplantation treatment for lower limb ischemia. International Angiology2017;36(4):346‐53. [PUBMED: 27958690] ">Gu 2017;</a><a href="./references#CD010747-bbs2-0042" title="GuoJ , GuoL , CuiS , TongZ , DardikA , GuY . Autologous bone marrow‐derived mononuclear cell therapy in Chinese patients with critical limb ischemia due to thromboangiitis obliterans: 10‐year results. Stem Cell Research &amp; Therapy2018;9(1):43. [PUBMED: 29471870] ">Guo 2018</a>; <a href="./references#CD010747-bbs2-0052" title="IafratiMD , O'Donnell JrTF , PerlerB , IlligKA , HallettJ , WooK , et al. SS03. Bone marrow aspirate concentrate in critical limb ischemia: results of an abridged prospective randomized pivotal trial in no option CLI. Abstracts of the 2016 Vascular Annual Meeting, The Society for Vascular Surgery2016;63(6 Suppl):47S. ">Iafrati 2016</a>; <a href="./references#CD010747-bbs2-0067" title="LiM , ZhouH , JinX , WangM , ZhangS , XuL . Autologous bone marrow mononuclear cells transplant in patients with critical leg ischemia: preliminary clinical results. Experimental and Clinical Transplantation2013;11(5):435‐9. [PUBMED: 23477421] ">Li 2013</a>; <a href="./references#CD010747-bbs2-0084" title="NCT00539266 . Autologous bone marrow‐derived mononuclear cells for therapeutic arteriogenesis in patients with limb ischemia (ABC). clinicaltrials.gov/ct2/show/NCT00539266(first received October 2007). ">NCT00539266</a>; <a href="./references#CD010747-bbs2-0086" title="NCT01049919 . Safety and efficacy study of autologous concentrated bone marrow aspirate (cBMA) for critical limb ischemia (CLI) (MOBILE). clinicaltrials.gov/ct2/show/NCT01049919 (first received 15 January 2010). ">NCT01049919</a>; <a href="./references#CD010747-bbs2-0087" title="NCT01245335 . Bone marrow aspirate concentrate (BMAC) for treatment of critical limb ischemia (CLI). clinicaltrials.gov/ct2/show/NCT01245335 (first received 22 November 2010). ">NCT01245335</a>; <a href="./references#CD010747-bbs2-0100" title="Peeters WeemSMO , TeraaM , denRuijterHM , deBorstGJ , VerhaarMC , MollFL . Quality of life after treatment with autologous bone marrow derived cells in no option severe limb ischemia. European Journal of Vascular and Endovascular Surgery2016;51(1):83‐9. ">Peeters 2016</a>; <a href="./references#CD010747-bbs2-0103" title="NCT00904501 . Bone marrow autograft in limb ischemia (BALI). clinicaltrials.gov/ct2/show/study/NCT00904501 (first received 19 May 2009). PignonB , SevestreMA , KanagaratnamL , PernodG , StephanD , EmmerichJ , et al. Autologous bone marrow mononuclear cell implantation and its impact on the outcome of patients with critical limb ischemia: results of a randomized, double‐blind, placebo‐controlled trial. Circulation Journal2017;81(11):1713‐20. [PUBMED: 28603176] ">Pignon 2017</a>; <a href="./references#CD010747-bbs2-0107" title="ProchazkaV , GumulecJ , JaluvkaF , SalounovaD , JonsztaT , CzernyD , et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplantation2010;19(11):1413‐24. [PUBMED: 20529449] ">Prochazka 2010</a>; <a href="./references#CD010747-bbs2-0116" title="Tateishi‐YuyamaE , MatsubaraH , MuroharaT , IkedaU , ShintaniS , MasakiH , et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone‐marrow cells: a pilot study and a randomised controlled trial. Lancet2002;360(9331):427‐35. [PUBMED: 12241713] ">Tateishi‐Yuyama 2002</a>; <a href="./references#CD010747-bbs2-0117" title="TeraaM , FledderusJO , RozbehRI , LeguitRJ , VerhaarMC . Bone marrow microvascular and neuropathic alterations in patients with critical limb ischemia. Circulation Research2014;114(2):311‐4. [PUBMED: 24218170] ">Teraa 2014</a>; <a href="./references#CD010747-bbs2-0118" title="SprengersRW , MollFL , TeraaM , VerhaarMC . Rationale and design of the JUVENTAS trial for repeated intra‐arterial infusion of autologous bone marrow‐derived mononuclear cells in patients with critical limb ischemia. Journal of Vascular Surgery2010;51(6):1564‐8. [PUBMED: 20488328] TeraaM , SprengersRW , SchutgensRE , Slaper‐CortenbachIC , van derGraafY , AlgraA , et al. Effect of repetitive intra‐arterial infusion of bone marrow mononuclear cells in patients with no‐option limb ischemia: the randomized, double‐blind, placebo‐controlled rejuvenating endothelial progenitor cells via transcutaneous intra‐arterial supplementation (JUVENTAS) trial. Circulation2015;131(10):851‐60. [PUBMED: 25567765] ">Teraa 2015</a>; <a href="./references#CD010747-bbs2-0120" title="NCT00282646 . Safety and feasibility study of autologous bone marrow cell transplantation in patients with PAOD. clinicaltrials.gov/ct2/show/study/NCT00282646 (first received 27 January 2006). WalterDH , KrankenbergH , BalzerJO , KalkaC , BaumgartnerI , SchluterM , et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized‐start, placebo‐controlled pilot trial (PROVASA). Circulation. Cardiovascular Interventions2011;4(1):26‐37. [PUBMED: 21205939] ">Walter 2011</a>; <a href="./references#CD010747-bbs2-0130" title="ZhouHM , LiuF , YangAG , GuoYQ , ZhouYR , GuYQ , et al. Efficacy, safety and influencing factors of intra‐calf muscular injection of bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus‐induced lower extremity vascular disease. Experimental and Therapeutic Medicine2017;14(5):5177‐85. [PUBMED: 29201234] ">Zhou 2017</a>), BM‐MSCs versus SMT (<a href="./references#CD010747-bbs2-0026" title="DashNR , DashSN , RoutrayP , MohapatraS , MohapatraPC . Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow‐derived mesenchymal stem cells. Rejuvenation Research2009;12(5):359‐66. [PUBMED: 19929258] ">Dash 2009</a>; <a href="./references#CD010747-bbs2-0028" title="DebinL , YouzhaoJ , ZiwenL , XiaoyanL , ZhonghuiZ , BingC . Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia. Journal of Medical Colleges of PLA2008;23(2):106‐15. ">Debin 2008</a>), concentrated bone marrow aspirate versus SMT (<a href="./references#CD010747-bbs2-0080" title="MurphyMP , RossCB , KibbeM , KelsoR , SharafuddinM , TzengE , et al. Intramuscular injection of autologous bone marrow cells to prevent amputation in critical limb ischemia: the results of the phase III MOBILE trial. Abstracts of the 2017 Vascular Annual Meeting2017;65(6 Suppl):131S‐2S. ">Murphy 2017</a>; <a href="./references#CD010747-bbs2-0083" title="NCT00434616 . Autologous bone marrow stem cell transplantation for critical, limb‐threatening ischemia (BONMOT). clinicaltrials.gov/ct2/show/NCT00434616 (first received 13 February 2007). ">NCT00434616</a>; <a href="./references#CD010747-bbs2-0122" title="WangSK , GreenL , BabbeyC , WilsonM , MotaganahalliR , FajardoA , et al. Ethnic minorities with critical limb ischemia derive equal amputation risk reduction from autologous cell therapy compared to Caucasians. Journal of Vascular Surgery2017;65(6):113S. WangSK , GreenLA , MotaganahalliRL , WilsonMG , FajardoA , MurphyMP . Rationale and design of the MarrowStim PAD Kit for the treatment of critical limb ischemia in subjects with severe peripheral arterial disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia. Journal of Vascular Surgery2017;65(6):1850‐7.e2. [PUBMED: 28390770] ">Wang 2017</a>), peripheral blood‐derived stem cell therapy versus SMT (<a href="./references#CD010747-bbs2-0030" title="DoudarN , ElAM , AbdelSS . Stem cell implantation in the treatment of peripheral vascular disease. Vox Sang2013;Suppl 1(105):290. ">Doudar 2013</a>; <a href="./references#CD010747-bbs2-0051" title="HuangP , LiS , HanM , XiaoZ , YangR , HanZC . Autologous transplantation of granulocyte colony‐stimulating factor‐mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care2005;28(9):2155‐60. [PUBMED: 16123483] NCT00730561 . Hematopoietic stem cell transplantation for the treatment of limb ischemia and diabetic neuropathy. clinicaltrials.gov/ct2/show/NCT00730561 (first received 8 August 2008). ">Huang 2005</a>; <a href="./references#CD010747-bbs2-0076" title="MohammadzadehL , SamedanifardSH , KeshavarziA , AlimoghaddamK , LarijaniB , GhavamzadehA , et al. Therapeutic outcomes of transplanting autologous granulocyte colony‐stimulating factor‐mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia. Experimental and Clinical Endocrinology &amp; Diabetes2013;121(1):48‐53. [PUBMED: 23329572] ">Mohammadzadeh 2013</a>; <a href="./references#CD010747-bbs2-0085" title="NCT00922389 . A clinical trial on diabetic foot using peripheral blood derived stem cells for treating critical limb ischemia. clinicaltrials.gov/ct2/show/NCT00922389 (first received 17 June 2009). ">NCT00922389</a>; <a href="./references#CD010747-bbs2-0095" title="NivenMJ , SivakG , KafriE , MosheM , GaliliO , FrogelM , et al. Adult stem/progenitor cells as a personalised treatment for peripheral vascular disease. Diabetologia. 2017; Vol. 60:S31. ">Niven 2017;</a><a href="./references#CD010747-bbs2-0097" title="OhtakeT , MochidaY , IshiokaK , OkaM , MaesatoK , MoriyaH , et al. Effect of autologous G‐CSF‐mobilized CD34+ cell transplantation in hemodialysis patients with critical limb ischemia. Nephrology Dialysis Transplantation2017;32(Suppl 3):iii309. ">Ohtake 2017</a>; <a href="./references#CD010747-bbs2-0099" title="OzturkA , KucukardaliY , TangiF , ErikciA , UzunG , BashekimC , et al. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. Journal of Diabetes and Its Complications2012;26(1):29‐33. [PUBMED: 22240264] ">Ozturk 2012</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1807100726519184119063355882252%26format=REVMAN#STD-Szabo-2013" target="_blank">Szabo 2013</a>), Ixmyelocel‐T versus SMT (<a href="./references#CD010747-bbs2-0106" title="PowellRJ , MarstonWA , BerceliSA , GuzmanR , HenryTD , LongcoreAT , et al. Cellular therapy with Ixmyelocel‐T to treat critical limb ischemia: the randomized, double‐blind, placebo‐controlled RESTORE‐CLI trial. Molecular Therapy2012;20(6):1280‐6. [PUBMED: 22453769] ">Powell 2012</a>), Rexmyelocel‐T versus SMT (<a href="./references#CD010747-bbs2-0090" title="NCT03174522 . The efficacy and safety of Rexmyelocel‐T to treat ischemic ulcers in subjects with CLI Rutherford category 5 and DM. clinicaltrials.gov/ct2/show/NCT03174522 (first received 2 June 2017). ">NCT03174522</a>), CD133+ cells versus SMT (<a href="./references#CD010747-bbs2-0128" title="ZhangX , LianW , LouW , HanS , LuC , ZuoK , et al. Transcatheter arterial infusion of autologous CD133(+) cells for diabetic peripheral artery disease. Stem Cells International2016;2016:6925357. [PUBMED: 26981134] ">Zhang 2016</a>), aldehyde dehydrogenase (ALDH) bright cells versus SMT (<a href="./references#CD010747-bbs2-0102" title="PerinEC , MurphyM , CookeJP , MoyeL , HenryTD , BettencourtJ , et al. Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells. American Heart Journal2014;168(5):667‐73. [PUBMED: 25440794] PerinEC , MurphyMP , MarchKL , BolliR , LoughranJ , YangPC , et al. Evaluation of cell therapy on exercise performance and limb perfusion in peripheral artery disease: the CCTRN PACE Trial (patients with intermittent claudication injected with ALDH bright cells). Circulation2017;135(15):1417‐28. ">Perin 2017</a>), vascular endothelial growth factor (VEGF) 165 gene‐modified PB CD34+ cells versus SMT (<a href="./references#CD010747-bbs2-0131" title="ZhouCH , XuLL , HaoXX , SunXJ , GuoMJ , LiuB . Autologous CD34+ cell transplantation promotes angiogenesis in older adult patients with atherosclerotic ischemia: study protocol for a prospective, single‐center, open‐label, randomized controlled clinical trial [外周血CD34+细胞自体移植促进老年动脉粥样性缺血肢体的血管新生：前瞻性、单中心、开放性、随机对照临床试验方案]. Chinese Journal of Tissue Engineering Research2017;21(13):1998‐2002. ">Zhou 2017a</a>), granulocyte macrophage‐stimulating factor (GM‐CSF) versus placebo (<a href="./references#CD010747-bbs2-0092" title="NCT03304821 . Granulocyte‐macrophage stimulating factor (GM‐CSF) in peripheral arterial disease. clinicaltrials.gov/ct2/show/NCT03304821 (first received 9 October 2017). ">NCT03304821</a>), and angiogenic cell precursors (ACPs) versus SMT (<a href="./references#CD010747-bbs2-0088" title="NCT01584986 . Autologous angiogenic cell precursors (ACPs) for the treatment of peripheral artery disease. clinicaltrials.gov/ct2/show/NCT01584986 (first received 25 April 2012). ">NCT01584986</a>). </p> </li> <li> <p>Forty‐two studies were single‐arm studies without a comparator/control arm. These studies investigated the safety and efficacy of bone marrow cells (<a href="./references#CD010747-bbs2-0020" title="ChocholaM , PytlikR , KobylkaP , SkalickaL , KideryovaL , BeranS , et al. Autologous intra‐arterial infusion of bone marrow mononuclear cells in patients with critical leg ischemia. International Angiology2008;27(4):281‐90. [PUBMED: 18677289] ">Chochola 2008</a>; <a href="./references#CD010747-bbs2-0023" title="CobellisG , BottiC , TaddeoA , SilvestroniA , LilloS , DaPonteA , et al. Successful bone marrow transplantation reveals the lack of endothelial progenitor cells mobilization in a patient with critical limb ischemia: a case report. Transplantation Proceedings2010;42(7):2816‐20. [PUBMED: 20832596] ">Cobellis 2010</a>; <a href="./references#CD010747-bbs2-0033" title="Duong Van HuyenJP , SmadjaDM , BrunevalP , GaussemP , Dal‐CortivoL , JuliaP , et al. Bone marrow‐derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia. Modern Pathology2008;21(7):837‐46. [PUBMED: 18487998] ">Duong 2008</a>; <a href="./references#CD010747-bbs2-0035" title="FranzRW , ParksA , ShahKJ , HankinsT , HartmanJF , WrightML . Use of autologous bone marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease. Journal of Vascular Surgery2009;50(6):1378‐90. [PUBMED: 19837539] FranzRW , ShahKJ , JohnsonJD , PinRH , ParksAM , HankinsT , et al. Short‐ to mid‐term results using autologous bone‐marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease. Vascular and Endovascular Surgery2011;45(5):398‐406. [PUBMED: 21669864] ">Franz 2011</a>; <a href="./references#CD010747-bbs2-0037" title="GabrH , HedayetA , ImamU , NasserM . Limb salvage using intramuscular injection of unfractionated autologous bone marrow mononuclear cells in critical limb ischemia: a prospective pilot clinical trial. Experimental and Clinical Transplantation2011;9(3):197‐202. [PUBMED: 21649569] ">Gabr 2011</a>; <a href="./references#CD010747-bbs2-0046" title="HeoSH , ParkYS , KangES , ParkKB , DoYS , KangKS , et al. Early results of clinical application of autologous whole bone marrow stem cell transplantation for critical limb ischemia with Buerger's disease. Scientific Reports2016;6:19690. [PUBMED: 26791280] ">Heo 2016;</a><a href="./references#CD010747-bbs2-0048" title="HigashiY , KimuraM , HaraK , NomaK , JitsuikiD , NakagawaK , et al. Autologous bone‐marrow mononuclear cell implantation improves endothelium‐dependent vasodilation in patients with limb ischemia. Circulation2004;109(10):1215‐8. [PUBMED: 15007007] ">Higashi 2004</a>; <a href="./references#CD010747-bbs2-0055" title="IsoY , SodaT , SatoT , SatoR , KusuyamaT , OmoriY , et al. Impact of implanted bone marrow progenitor cell composition on limb salvage after cell implantation in patients with critical limb ischemia. Atherosclerosis2010;209(1):167‐72. [PUBMED: 19748620] ">Iso 2010</a>; <a href="./references#CD010747-bbs2-0060" title="KolvenbachR , KreissigC , CagiannosC , AfifiR , SchmaltzE . Intraoperative adjunctive stem cell treatment in patients with critical limb ischemia using a novel point‐of‐care device. Annals of Vascular Surgery2010;24(3):367‐72. [PUBMED: 19896796] ">Kolvenbach 2010</a>; <a href="./references#CD010747-bbs2-0062" title="KondoK , YanishiK , HayashidaR , ShintaniS , ShibataR , MurotaniK , et al. Long‐term clinical outcomes survey of bone marrow‐derived cell therapy in critical limb ischemia in Japan. Circulation Journal2018;82(4):1168‐78. [PUBMED: 29386474] ">Kondo 2018;</a><a href="./references#CD010747-bbs2-0070" title="MaioneC , BottiC , CoppolaCA , SilvestroniC , LilloS , SchiavoneV , et al. Effect of autologous transplantation of bone marrow cells concentrated with the MarrowXpress system in patients with critical limb ischemia. Transplantation Proceedings2013;45(1):402‐6. [PUBMED: 23375329] ">Maione 2013</a>; <a href="./references#CD010747-bbs2-0072" title="MalyarNM , RadtkeS , MalyarK , ArjumandJ , HornPA , KrögerK , et al. Autologous bone marrow mononuclear cell therapy improves symptoms in patients with end‐stage peripheral arterial disease and reduces inflammation‐associated parameters. Cytotherapy2014;16(9):1270‐9. ">Malyar 2014</a>; <a href="./references#CD010747-bbs2-0073" title="MatobaS , TatsumiT , MuroharaT . Long‐term clinical outcome after intramuscular implantation of bone barrow mononuclear cells (therapeutic angiogenesis by cell transplantation [TACT] Trial) in patients with chronic limb ischemia. American Heart Journal2009;50(1):233. ">Matoba 2009</a>; <a href="./references#CD010747-bbs2-0078" title="MotukuruV , SureshKR , VivekanandV , RajS , GirijaKR . Therapeutic angiogenesis in Buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. Journal of Vascular Surgery2008;48(6 Suppl):53S‐60S; discussion 60S. [PUBMED: 19084740] ">Motukuru 2008</a>; <a href="./references#CD010747-bbs2-0079" title="MurphyMP , LawsonJH , RappBM , DalsingMC , KleinJ , WilsonMG , et al. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation‐free survival in patients with critical limb ischemia. Journal of Vascular Surgery2011;53(6):1565‐74.e1. [PUBMED: 21514773] ">Murphy 2011</a>; <a href="./references#CD010747-bbs2-0082" title="CobellisG , BottiC , TaddeoA , SilvestroniA , LilloS , DaPonteA , et al. Successful bone marrow transplantation reveals the lack of endothelial progenitor cells mobilization in a patient with critical limb ischemia: a case report. Transplantation Proceedings2010;42(7):2816‐20. [PUBMED: 20832596] MaioneC , BottiC , CoppolaCA , SilvestroniC , LilloS , SchiavoneV , et al. Effect of autologous transplantation of bone marrow cells concentrated with the MarrowXpress system in patients with critical limb ischemia. Transplantation Proceedings2013;45(1):402‐6. [PUBMED: 23375329] NCT00306085 . Autologous bone marrow cell treatment in peripheral atherosclerosis. clinicaltrials.gov/ct2/show/study/NCT00306085 (first received 22 March 2006). NapoliC , FarzatiB , SicaV , IannuzziE , CoppolaG , SilvestroniA , et al. Beneficial effects of autologous bone marrow cell infusion and antioxidants/L‐arginine in patients with chronic critical limb ischemia. European Journal of Cardiovascular Prevention and Rehabilitation2008;15(6):709‐18. [PUBMED: 19050436] ">NCT00306085</a>; <a href="./references#CD010747-bbs2-0096" title="NizankowskiR , PetriczekT , SkotnickiA , SzczeklikA . The treatment of advanced chronic lower limb ischaemia with marrow stem cell autotransplantation. Kardiologia Polska2005;63(4):351‐60; discussion 361. [PUBMED: 16273471] ">Nizankowski 2005</a>; <a href="./references#CD010747-bbs2-0104" title="PonemoneV , GuptaS , SethiD , SutharM , SharmaM , PowellRJ , et al. Safety and effectiveness of bone marrow cell concentrate in the treatment of chronic critical limb ischemia utilizing a rapid point‐of‐care system. Stem Cells International2017;2017:4137626. [PUBMED: 28194186] ">Ponemone 2017</a>; <a href="./references#CD010747-bbs2-0109" title="Ruiz‐SalmeronR , de laCuesta‐DiazA , Constantino‐BermejoM , Perez‐CamachoI , Marcos‐SanchezF , HmadchaA , et al. Angiographic demonstration of neoangiogenesis after intra‐arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia. Cell Transplantation2011;20(10):1629‐39. [PUBMED: 22289660] ">Ruiz‐Salmeron 2011</a>; <a href="./references#CD010747-bbs2-0110" title="SaitoY , SasakiK , KatsudaY , MuroharaT , TakeshitaY , OkazakiT , et al. Effect of autologous bone‐marrow cell transplantation on ischemic ulcer in patients with Buerger's disease. Circulation Journal2007;71(8):1187‐92. [PUBMED: 17652879] ">Saito 2007</a>; <a href="./references#CD010747-bbs2-0111" title="SchiavettaA , MaioneC , BottiC , MarinoG , LilloS , GarroneA , et al. A phase II trial of autologous transplantation of bone marrow stem cells for critical limb ischemia: results of the Naples and Pietra Ligure Evaluation of Stem Cells study. Stem Cells Translational Medicine2012;1(7):572‐8. [PUBMED: 23197862] ">Schiavetta 2012</a>; <a href="./references#CD010747-bbs2-0124" title="WesterT , JorgensenJJ , StrandenE , SandbaekG , TjonnfjordG , BayD , et al. Treatment with autologous bone marrow mononuclear cells in patients with critical lower limb ischaemia. A pilot study. Scandinavian Journal of Surgery2008;97(1):56‐62. [PUBMED: 18450207] ">Wester 2008</a>; <a href="./references#CD010747-bbs2-0126" title="YanishiK , NakanishiN , ZenK , OgataT , NakamuraT , YamanoT , et al. Long‐term clinical outcome of therapeutic angiogenesis by cell transplantation in patients with critical limb ischemia. European Heart Journal.2017;38(Suppl 1):1080. ">Yanishi 2017</a>), PBSCs (<a href="./references#CD010747-bbs2-0050" title="HoshinoJ , UbaraY , HaraS , SogawaY , SuwabeT , HigaY , et al. Quality of life improvement and long‐term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis. Circulation Journal2007;71(8):1193‐8. [PUBMED: 17652880] ">Hoshino 2007</a>; <a href="./references#CD010747-bbs2-0054" title="IshidaA , OhyaY , SakudaH , OhshiroK , HigashiuesatoY , NakaemaM , et al. Autologous peripheral blood mononuclear cell implantation for patients with peripheral arterial disease improves limb ischemia. Circulation Journal2005;69(10):1260‐5. [PUBMED: 16195628] ">Ishida 2005</a>; <a href="./references#CD010747-bbs2-0057" title="KawamotoA , KatayamaM , HandaN , KinoshitaM , TakanoH , HoriiM , et al. Intramuscular transplantation of G‐CSF‐mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single‐blinded, dose‐escalation clinical trial. Stem Cells2009;27(11):2857‐64. [PUBMED: 19711453] ">Kawamoto 2009</a>; <a href="./references#CD010747-bbs2-0058" title="KinoshitaM , FujitaY , KatayamaM , BabaR , ShibakawaM , YoshikawaK , et al. Long‐term clinical outcome after intramuscular transplantation of granulocyte colony stimulating factor‐mobilized CD34 positive cells in patients with critical limb ischemia. Atherosclerosis2012;224(2):440‐5. [PUBMED: 22877866] ">Kinoshita 2012</a>; <a href="./references#CD010747-bbs2-0063" title="Lara‐HernandezR , Lozano‐VilardellP , BlanesP , Torreguitart‐MiradaN , GalmesA , BesalduchJ . Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia. Annals of Vascular Surgery2010;24(2):287‐94. [PUBMED: 20142004] ">Lara‐Hernandez 2010</a>; <a href="./references#CD010747-bbs2-0068" title="MadaricJ , KlepanecA , ValachovicovaM , MistrikM , BucovaM , OlejarovaI , et al. Characteristics of responders to autologous bone marrow cell therapy for no‐option critical limb ischemia. Stem Cell Research &amp; Therapy2016;7(1):116. [PUBMED: 27530339] ">Madaric 2016</a>), PB‐MNCs (<a href="./references#CD010747-bbs2-0010" title="AmatoB , CompagnaR , Della CorteGA , MartinoG , BiancoT , CorettiG , et al. Peripheral blood mono‐nuclear cells implantation in patients with peripheral arterial disease: a pilot study for clinical and biochemical outcome of neoangiogenesis. BMC Surgery2012;12(Suppl 1):S1. [PUBMED: 23173612] ">Amato 2012</a>; <a href="./references#CD010747-bbs2-0077" title="MoriyaJ , MinaminoT , TatenoK , ShimizuN , KuwabaraY , SatoY , et al. Long‐term outcome of therapeutic neovascularization using peripheral blood mononuclear cells for limb ischemia. Circulation. Cardiovascular Interventions2009;2(3):245‐54. [PUBMED: 20031722] ">Moriya 2009</a>), adipose tissue stem cells (<a href="./references#CD010747-bbs2-0017" title="BuraA , Planat‐BenardV , BourinP , SilvestreJS , GrossF , GrolleauJL , et al. Phase I trial: the use of autologous cultured adipose‐derived stroma/stem cells to treat patients with non‐revascularizable critical limb ischemia. Cytotherapy2014;16(2):245‐57. [PUBMED: 24438903] ">Bura 2014</a>; <a href="./references#CD010747-bbs2-0024" title="DarinskasA , PaskeviciusM , ApanaviciusG , VilkeviciusG , LabanauskasL , IchimTE , et al. Stromal vascular fraction cells for the treatment of critical limb ischemia: a pilot study. Journal of Translational Medicine2017;15(1):143. [PUBMED: 28629476] ">Darinskas 2017;</a><a href="./references#CD010747-bbs2-0061" title="KondoK , HayashidaR , ShibataR , MuroharaT . Therapeutic angiogenesis for critical limb ischemia by implantation of autologous adipose‐derived regenerative cells: a clinical pilot study. Circulation2016;134(Suppl 1):A18595. ">Kondo 2016</a>; <a href="./references#CD010747-bbs2-0065" title="LeeHC , AnSG , LeeHW , ParkJS , ChaKS , HongTJ , et al. Safety and effect of adipose tissue‐derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circulation Journal2012;76(7):1750‐60. [PUBMED: 22498564] ">Lee 2012</a>), BM‐MSCs plus BM‐MNCs (<a href="./references#CD010747-bbs2-0064" title="LasalaGP , SilvaJA , GardnerPA , MinguellJJ . Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis. Angiology2010;61(6):551‐6. [PUBMED: 20498146] ">Lasala 2010</a>), BM‐MSCs (<a href="./references#CD010747-bbs2-0075" title="MohamedS , McInerneyV , DunneA , HayatA , KrawczykJ , NaughtonS , et al. Autologous mesenchymal stem cells as a novel therapy for no‐option critical limb ischemia: preliminary results of a phase 1 study. Cytotherapy2017;19(5):S198. MohamedS , McInerneyV , DunneA , HayatA , KrawczykJ , NaughtonS , et al. Autologous mesenchymal stem cells as a novel therapy for no‐option critical limb ischemia: preliminary results of a phase 1 study. Irish Journal of Medical Science2017;186(Suppl 2):S82. ">Mohamed 2017</a>), peripheral blood CD133+ cells (<a href="./references#CD010747-bbs2-0012" title="AriciV , PerottiC , FabrizioC , DelFanteC , RagniF , AlessandrinoF , et al. Autologous immuno magnetically selected CD133+ stem cells in the treatment of no‐option critical limb ischemia: clinical and contrast enhanced ultrasound assessed results in eight patients. Journal of Translational Medicine2015;13:342. [PUBMED: 26526721] ">Arici 2015</a>; <a href="./references#CD010747-bbs2-0018" title="BurtRK , TestoriA , OyamaY , RodriguezHE , YaungK , VillaM , et al. Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplantation2010;45(1):111‐6. [PUBMED: 19448678] ">Burt 2010</a>), circulating blood‐derived progenitor cells (<a href="./references#CD010747-bbs2-0036" title="FrogelM , NivenMJ , GaliliO , SivakG , KafriE , MosheM , et al. Adult stem/progenitor cells derived from peripheral blood as a personalized treatment for critical limb ischemia (CLI). Vascular2017;25(2 Suppl 1):88. ">Frogel 2017</a>; <a href="./references#CD010747-bbs2-0066" title="LenkK , AdamsV , LurzP , ErbsS , LinkeA , GielenS , et al. Therapeutical potential of blood‐derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. European Heart Journal2005;26(18):1903‐9. [PUBMED: 15855189] ">Lenk 2005</a>), and venous endothelial and smooth muscle cells, called MultiGeneAngio (MGA) (<a href="./references#CD010747-bbs2-0038" title="GrossmanPM , MohlerER3rd , RoesslerBJ , WilenskyRL , LevineBL , WooEY , et al. Phase I study of multi‐gene cell therapy in patients with peripheral artery disease. Vascular Medicine (London, England)2016;21(1):21‐32. [PUBMED: 26584888] ">Grossman 2016</a>). </p> </li> <li> <p>Eleven studies were comparative non‐randomised studies. These studies investigated the effects of BM‐MNCs versus mPBSCs (<a href="./references#CD010747-bbs2-0032" title="DubskyM , JirkovskaA , BemR , FejfarovaV , PagacovaL , SixtaB , et al. Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment. Diabetes/Metabolism Research and Reviews2013;29(5):369‐76. [PUBMED: 23390092] ">Dubsky 2013</a>; <a href="./references#CD010747-bbs2-0040" title="GuY , ZhangJ , QiL . [Comparative study on autologous implantation between bone marrow stem cells and peripheral blood stem cells for treatment of lower limb ischemia]. Zhongguo Xiu fu Chong Jian Wai ke za Zhi = Zhongguo Xiufu Chongjian Waike Zazhi = Chinese Journal of Reparative and Reconstructive Surgery2007;21(7):675‐8. [PUBMED: 17694651] ">Gu 2007</a>; <a href="./references#CD010747-bbs2-0056" title="KamataY , TakahashiY , IwamotoM , MatsuiK , MurakamiY , MuroiK , et al. Local implantation of autologous mononuclear cells from bone marrow and peripheral blood for treatment of ischaemic digits in patients with connective tissue diseases. Rheumatology (Oxford, England)2007;46(5):882‐4. [PUBMED: 17309890] ">Kamata 2007</a>; <a href="./references#CD010747-bbs2-0074" title="MatsuiK , MurakamiY , YoshiokaT , MuroiK , KasudaH , ShimpoM , et al. Therapeutic angiogenesis by transplantation of autologous bone marrow and peripheral blood mononuclear cells in patients with peripheral arterial disease. International Journal of Angiology2003;12:155–61. ">Matsui 2003</a>), BM‐MNCs versus control (<a href="./references#CD010747-bbs2-0014" title="BartschT , BrehmM , ZeusT , KoglerG , WernetP , StrauerBE . Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (the TAM‐PAD study). Clinical Research in Cardiology2007;96(12):891‐9. [PUBMED: 17694378] ">Bartsch 2007</a>; <a href="./references#CD010747-bbs2-0022" title="CobellisG , SilvestroniA , LilloS , SicaG , BottiC , MaioneC , et al. Long‐term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplantation2008;42(10):667‐72. [PUBMED: 18695661] ">Cobellis 2008</a>; <a href="./references#CD010747-bbs2-0053" title="IdeiN , SogaJ , HataT , FujiiY , FujimuraN , MikamiS , et al. Autologous bone‐marrow mononuclear cell implantation reduces long‐term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circulation. Cardiovascular Interventions2011;4(1):15‐25. [PUBMED: 21205941] ">Idei 2011</a>; <a href="./references#CD010747-bbs2-0081" title="NapoliC , FarzatiB , SicaV , IannuzziE , CoppolaG , SilvestroniA , et al. Beneficial effects of autologous bone marrow cell infusion and antioxidants/L‐arginine in patients with chronic critical limb ischemia. European Journal of Cardiovascular Prevention and Rehabilitation2008;15(6):709‐18. [PUBMED: 19050436] ">Napoli 2008</a>), PB‐MNCs versus control (<a href="./references#CD010747-bbs2-0027" title="DeAngelisB , GentileP , OrlandiF , BocchiniI , DiPasqualiC , AgovinoA , et al. Limb rescue: a new autologous‐peripheral blood mononuclear cells technology in critical limb ischemia and chronic ulcers. Tissue Engineering. Part C, Methods2014;21(5):423‐35. [PUBMED: 25341088] ">De Angelis 2014</a>), circulating blood‐derived progenitor cells versus control (<a href="./references#CD010747-bbs2-0094" title="NemcovaA , JirkovskaA , DubskyM , BemR , FejfarovaV , PysnaA , et al. Serum levels of angiogenic cytokines in the assessment of vasculogenesis after autologous cell therapy in diabetic patients with critical limb ischaemia. Diabetologia. 2017; Vol. 60:S468. ">Nemcova 2017</a>), and low versus high cell dose used for implantation (<a href="./references#CD010747-bbs2-0039" title="GuY , ZhangJ , QiL . Effective autologous bone marrow stem cell dosage for treatment of severe lower limb ischemia. Zhongguo Xiu fu Chong Jian Wai ke za Zhi = Zhongguo Xiufu Chongjian Waike Zazhi = Chinese Journal of Reparative and Reconstructive Surgery2006;20(5):504‐6. [PUBMED: 16752834] ">Gu 2006</a>). </p> </li> <li> <p>In three studies, the study populations were not CLI patients (<a href="./references#CD010747-bbs2-0016" title="BingC , De‐binL , Zi‐wenL , You‐zaoJ , Fu‐huaW , Qi‐nanW , et al. Autologous bone marrow mesenchymal stem cell transplantation for treatment of diabetic foot following amplification in vitro. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13:6227‐30. ">Bing 2009</a>; <a href="./references#CD010747-bbs2-0049" title="HolzingerC , ZuckermannA , KoppC , SchollhammerA , ImhofM , ZwolferW , et al. Treatment of non‐healing skin ulcers with autologous activated mononuclear cells. European Journal of Vascular Surgery1994;8(3):351‐6. [PUBMED: 8013688] ">Holzinger 1994</a>; <a href="./references#CD010747-bbs2-0113" title="SubramaniyamV , WallerEK , MurrowJR , ManatungaA , LonialS , KasirajanK , et al. Bone marrow mobilization with granulocyte macrophage colony‐stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease. American Heart Journal2009;158(1):53‐60.e1. [PUBMED: 19540392] ">Subramaniyam 2009</a>). </p> </li> <li> <p>Nine studies used allogeneic mesenchymal stem cells (MSCs) instead of autologous MSCs (<a href="./references#CD010747-bbs2-0025" title="DasAK , Bin AbdullahBJ , DhillonSS , VijanariA , AnoopCH , GuptaPK . Intra‐arterial allogeneic mesenchymal stem cells for critical limb ischemia are safe and efficacious: report of a phase I study. World Journal of Surgery2013;37(4):915‐22. [PUBMED: 23307180] ">Das 2013</a>; <a href="./references#CD010747-bbs2-0031" title="DuJW , WuT , ZhangK , SuBY , LuCP , WangWC , et al. Umbilical cord mesenchymal stem cells combined with bone marrow stem cells for treatment of lower limb ischemia [脐带间充质干细胞联合骨髓干细胞治疗下肢缺血]. Chinese Journal of Tissue Engineering Research2017;21(1):82‐6. ">Du 2017;</a><a href="./references#CD010747-bbs2-0043" title="GuptaPK , ChullikanaA , ParakhR , DesaiS , DasA , GottipamulaS , et al. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. Journal of Translational Medicine2013;11:143. [PUBMED: 23758736] ">Gupta 2013</a>; <a href="./references#CD010747-bbs2-0044" title="GuptaPK , ChullikanaA , RajkumarM , KrishnaM , DuttaS , SarkarU , et al. Role of bone marrow derived allogeneic mesenchymal stromal cells (Stempeucel) in critical limb ischemia due to Buerger's disease‐efficacy and safety results of non‐randomized, open label, multicentric, dose ranging, phase II study in India. Cytotherapy2014;16(4):S80‐1. GuptaPK , KrishnaM , ChullikanaA , DesaiS , MurugesanR , DuttaS . Administration of adult human bone marrow‐derived, cultured, pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due to Buerger's disease: phase II study report suggests clinical efficacy. Journal of Vascular Surgery2017;66(4):1303. GuptaPK , KrishnaM , ChullikanaA , DesaiS , MurugesanR , DuttaS , et al. Administration of adult human bone marrow‐derived, cultured, pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due to Buerger's disease: phase II study report suggests clinical efficacy. Stem Cells Translational Medicine2017;6(3):689‐99. ">Gupta 2017</a>; <a href="./references#CD010747-bbs2-0071" title="MajumdarAS , BalasubramanianS , ThejC , RajkumarM , KrishnaM , DuttaS , et al. A first of its kind phase II clinical trial in critical limb ischemia patients using bone marrow derived, pooled, allogeneic mesenchymal stromal cells (Stempeucel). Cytotherapy2015; Vol. 17:S84. ">Majumdar 2015;</a><a href="./references#CD010747-bbs2-0089" title="NCT02336646 . Cell therapy with mesenchymal stem cell in ischemic limb disease. clinicaltrials.gov/ct2/show/NCT02336646 (first received 13 January 2015). ">NCT02336646</a>; <a href="./references#CD010747-bbs2-0093" title="NCT03339973 . Allogeneic ABCB5‐positive stem cells for treatment of PAOD. clinicaltrials.gov/ct2/show/NCT03339973 (first received 13 November 2017). ">NCT03339973</a>; <a href="./references#CD010747-bbs2-0123" title="WangSK , GreenLA , DruckerNA , MotaganahalliRL , FajardoA , MurphyMP . Rationale and design of the Clinical and Histologic Analysis of Mesenchymal stromal cells in amPutations (CHAMP) trial investigating the therapeutic mechanism of mesenchymal stromal cells in the treatment of critical limb ischemia. Journal of Vascular Surgery2018;68(1):176‐81.e1. [PUBMED: 29395424] ">Wang 2018;</a><a href="./references#CD010747-bbs2-0125" title="NCT03042572 . Allogeneic mesenchymal stromal cells for angiogenesis and neovascularization in no‐option ischemic limbs (SAIL). clinicaltrials.gov/ct2/show/NCT03042572 (first received 3 February 2017). WijnandJGJ , TeraaM , GremmelsH , vanRhijn‐BrouwerFCC , deBorstGJ , VerhaarMC . Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no‐option critical limb ischemia. Journal of Vascular Surgery2018;67(2):656‐61. [PUBMED: 29242062] ">Wijnand 2018</a>). </p> </li> <li> <p>In one study, the agent used in the intervention group was not a cell‐based product (<a href="./references#CD010747-bbs2-0108" title="RajagopalanS , MohlerE3rd , LedermanRJ , SaucedoJ , MendelsohnFO , OlinJ , et al. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. American Heart Journal2003;145(6):1114‐8. [PUBMED: 12796772] ">Rajagopalan 2003</a>). </p> </li> <li> <p>Three studies investigated the therapeutic effects of growth factors (GM‐CSF and G‐CSF) instead of cell‐based products (<a href="./references#CD010747-bbs2-0021" title="ChoiET , GeraghtyP , CookeC , SchechtmanK , LinkD , ChambersCM , VeeraswamyRK . Stem cell mobilization to treat severe peripheral artery disease (STEMPAD). Vascular Annual Meeting2012:LB7. NCT00797056 . Stem cell mobilization by G‐CSF to treat severe peripheral artery disease. clinicaltrials.gov/ct2/show/NCT00797056 (first received 25 November 2008). ">Choi 2012</a>; <a href="./references#CD010747-bbs2-0105" title="PooleJ , MavromatisK , BinongoJN , KhanA , LiQ , KhayataM , et al. Effect of progenitor cell mobilization with granulocyte‐macrophage colony‐stimulating factor in patients with peripheral artery disease: a randomized clinical trial. JAMA2013;310(24):2631‐9. [PUBMED: 24247554] ">Poole 2013</a>; <a href="./references#CD010747-bbs2-0127" title="ZafarghandiMR , RavariH , AghdamiN , NamiriM , MoazzamiK , TaghiabadiE , et al. Safety and efficacy of granulocyte‐colony‐stimulating factor administration following autologous intramuscular implantation of bone marrow mononuclear cells: a randomized controlled trial in patients with advanced lower limb ischemia. Cytotherapy2010;12(6):783‐91. [PUBMED: 20078390] ">Zafarghandi 2010</a>). </p> </li> <li> <p>Two studies compared cell treatment versus treatment with non‐cell‐based products (<a href="./references#CD010747-bbs2-0115" title="TakagiG , MiyamotoM , TaraS , TakagiI , TakanoH , YasutakeM , et al. Controlled‐release basic fibroblast growth factor for peripheral artery disease: comparison with autologous bone marrow‐derived stem cell transfer. Tissue Engineering. Part A2011;17(21‐22):2787‐94. [PUBMED: 21810028] ">Takagi 2011</a>; <a href="./references#CD010747-bbs2-0121" title="WangX , JiangL , WangX , YinF , LiG , FengX , et al. Combination of autologous transplantation of G‐CSF‐mobilized peripheral blood mononuclear cells and Panax notoginseng saponins in the treatment of unreconstructable critical limb ischemia. Annals of Vascular Surgery2014;28(6):1501‐12. [PUBMED: 24632316] ">Wang 2014</a>). </p> </li> <li> <p>Two studies investigated specialised cell‐based products derived via specific isolation and culture methods (<a href="./references#CD010747-bbs2-0059" title="KiranaS , StratmannB , PranteC , ProhaskaW , KoerperichH , LammersD , et al. Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients. International Journal of Clinical Practice2012;66(4):384‐93. [PUBMED: 22284892] NCT01065337 . Induced wound healing by application of expanded bone marrow stem cells in diabetic patients with critical limb ischemia. clinicaltrials.gov/ct2/show/NCT01065337(first received 9 February 200). ">Kirana 2012</a>; <a href="./references#CD010747-bbs2-0101" title="PerinEC , SilvaG , GahremanpourA , CanalesJ , ZhengY , Cabreira‐HansenMG , et al. A randomized, controlled study of autologous therapy with bone marrow‐derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheterization and Cardiovascular Interventions2011;78(7):1060‐7. [PUBMED: 21594960] ">Perin 2011</a>). Significant variation in the final product injected into participants precluded inclusion of these studies in our systematic review. </p> </li> <li> <p>Three studies co‐administered two different sources of autologous stem cells into the affected limb: BM‐MNCs combined with mPBSCs (<a href="./references#CD010747-bbs2-0129" title="ZhaoZG , YuanHJ , ZhangHF , ZhangCL , WangYF , MaSP , et al. Combined transplantation of autologous peripheral blood and bone marrow stem cells for the treatment of diabetic lower limb ischaemia: randomized controlled trial. [Chinese]. Journal of Clinical Rehabilitative Tissue Engineering Research2008;12(8):1464‐6. ">Zhao 2008</a>), BM‐MSCs with BM‐MNCs versus BM‐MNCs alone (<a href="./references#CD010747-bbs2-0045" title="HarunarashidH , Mohd IdrisM , ChinS , Mohamad YusoffF , ShahariS , Amran@AzmanN , et al. Combination BM‐MSC with BM‐MNC is better than BM‐MNC alone in resolution of large ischemic ulcers: a phase II/III clinical randomised study. 22nd Annual ISCT Meeting2016;18(6 Suppl):S21. ">Harunarashid 2016</a>), and venous endothelial cells (ECs) combined with venous smooth muscle cells (SMCs) (<a href="./references#CD010747-bbs2-0034" title="FlugelmanMY , HalakM , YoffeB , SchneidermanJ , RubinsteinC , BloomAI , et al. Phase Ib safety, two‐odse study of MultiGeneAngio in patients with chronic critical limb ischemia. Molecular Therapy2017;25(3):816‐25. [PUBMED: 28143739] ">Flugelman 2017</a>). </p> </li> <li> <p>One study compared the clinical outcomes of CLI patients treated with one type of stem cell (BM‐MNC) that was separated via two different methods (<a href="./references#CD010747-bbs2-0047" title="HernandezP , CortinaL , ArtazaH , PolN , LamRM , DorticosE , et al. Autologous bone‐marrow mononuclear cell implantation in patients with severe lower limb ischaemia: a comparison of using blood cell separator and Ficoll density gradient centrifugation. Atherosclerosis2007;194(2):e52‐6. [PUBMED: 16982058] ">Hernandez 2007</a>). </p> </li> <li> <p>One study compared the clinical outcomes of CLI patients treated with BM‐MNCs versus mPBSCs by performing a pooled analysis using data from two previous cohort studies (<a href="./references#CD010747-bbs2-0098" title="OnoderaR , TeramukaiS , TanakaS , KojimaS , HorieT , MatobaS , et al. Bone marrow mononuclear cells versus G‐CSF‐mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long‐term prognosis. Bone Marrow Transplantation2011;46(2):278‐84. [PUBMED: 20479708] ">Onodera 2011</a>). </p> </li> <li> <p>Two studies investigated the count and phenotype of cells used for implantation and did not study the clinical outcomes after cell implantation (<a href="./references#CD010747-bbs2-0019" title="CapiodJC , TournoisC , VitryF , SevestreMA , DaliphardS , ReixT , et al. Characterization and comparison of bone marrow and peripheral blood mononuclear cells used for cellular therapy in critical leg ischaemia: towards a new cellular product. Vox Sanguinis2009;96(3):256‐65. [PUBMED: 19207166] ">Capiod 2009</a>; <a href="./references#CD010747-bbs2-0112" title="SmadjaDM , Duong‐van‐HuyenJP , Dal CortivoL , BlanchardA , BrunevalP , EmmerichJ , et al. Early endothelial progenitor cells in bone marrow are a biomarker of cell therapy success in patients with critical limb ischemia. Cytotherapy2012;14(2):232‐9. [PUBMED: 22040109] ">Smadja 2012</a>). </p> </li> <li> <p>One study investigated the thrombogenicity of the transplanted cell and did not study clinical outcomes after cell implantation (<a href="./references#CD010747-bbs2-0119" title="TournoisC , PignonB , SevestreMA , DjeradaZ , CapiodJC , PoitevinG , et al. Critical limb ischemia: thrombogenic evaluation of two autologous cell therapy products and biologic profile in treated patients. Transfusion2015;55(11):2692‐701. [PUBMED: 26222701] ">Tournois 2015</a>). </p> </li> <li> <p>One study investigated the number of endothelial progenitor cells (EPCs) in PAD patients and did not study clinical outcomes after cell implantation (<a href="./references#CD010747-bbs2-0008" title="AfanS , BitterliL , BuhlerS , DiSantoS , ZwahlenM , SchmidlinK , et al. Endothelial progenitor cells as biological marker of peripheral arterial disease. Vasa‐European Journal of Vascular Medicine2015;44(Suppl 88):59‐60. ">Afan 2015</a>). </p> </li> <li> <p>One study investigated the level of asymmetric dimethylarginine (ADMA) and changes in oxidative stress in patients with CLI after BM‐MNC therapy and did not study clinical outcomes of cell treatment (<a href="./references#CD010747-bbs2-0069" title="MadaricJ , ValachovicovaM , PaulisL , PribojovaJ , MateovaR , SebekovaK , et al. Improvement in asymmetric dimethylarginine and oxidative stress in patients with limb salvage after autologous mononuclear stem cell application for critical limb ischemia. Stem Cell Research &amp; Therapy2017;8(1):165. [PUBMED: 28697789] ">Madaric 2017</a>). </p> </li> <li> <p>One study investigated the safety and efficacy of hyaluronic acid (HA) combined with BM‐MNCs for patients with PAD (<a href="https://archie.cochrane.org/sections/documents/view?version=z1807130851333128903954766489628%26format=REVMAN#STD-NCT03214887" target="_blank">NCT03214887</a>). </p> </li> </ol> </p> </section> </section> <section id="CD010747-sec-0084"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD010747-fig-0002">Figure 2</a> and <a href="#CD010747-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010747-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010747-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010747-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010747-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010747-sec-0085"> <h4 class="title">Allocation</h4> <p>We judged six studies as having low risk of bias for random sequence generation (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>; <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>). One RCT had unclear risk of bias for random sequence generation, as study authors did not explicitly state the method of sequence generation used (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). We graded allocation concealment as causing unclear risk in all studies because papers provided insufficient information. </p> </section> <section id="CD010747-sec-0086"> <h4 class="title">Blinding</h4> <p>Five studies had high risk of performance bias. In two RCTs, both physicians and patients were unblinded to the different techniques used in autologous cell collection (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>), and in three studies, both physicians and patients were unblinded to the different routes of cell implantation employed (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>). We deemed the remaining two included studies to have low risk of performance bias (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>; <a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> <p>Four studies had unclear detection bias, as study authors did not mention whether outcome assessors were blinded to patients' assigned groups (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>). We deemed the remaining three included studies to have low risk of detection bias (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>; <a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>). </p> </section> <section id="CD010747-sec-0087"> <h4 class="title">Incomplete outcome data</h4> <p>One study reported that six participants (two in one group and four in another) were excluded before the implantation and 10 participants (four in one group and six in another) discontinued after amputation (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>). Another study reported that eight participants (28.6%) did not complete the 12‐month study period (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). We judged both studies to have high risk of attrition bias owing to unequal numbers of dropouts between groups and high overall dropout rates. The remaining studies had low risk of bias in this domain. </p> </section> <section id="CD010747-sec-0088"> <h4 class="title">Selective reporting</h4> <p>We judged three studies as having high risk of reporting bias because study authors provided incomplete outcome information (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>; <a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>); we considered the remaining studies to have low risk of reporting bias. </p> </section> <section id="CD010747-sec-0089"> <h4 class="title">Other potential sources of bias</h4> <p>We screened for other potential sources of bias including extreme baseline imbalance and unit of analysis issues. We identified four studies with unit of analysis issues (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>; <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>). We judged the remaining included studies to have low risk of other potential sources of bias. Cell doses for MNCs and stem cells cannot be equated, as &lt; 0.01% of MNCs consisted of stem cells. Therefore, an analysis of cell doses would have been intrinsically biased. </p> </section> </section> <section id="CD010747-sec-0090"> <h3 class="title" id="CD010747-sec-0090">Effects of interventions</h3> <p>See: <a href="./full#CD010747-tbl-0001"><b>Summary of findings for the main comparison</b> BM‐MNCs compared to mPBSCs for critical lower limb ischaemia</a>; <a href="./full#CD010747-tbl-0002"><b>Summary of findings 2</b> BM‐MNCs compared to BM‐MSCs for critical lower limb ischaemia</a>; <a href="./full#CD010747-tbl-0003"><b>Summary of findings 3</b> High cell dose compared to low cell dose for critical lower limb ischaemia</a>; <a href="./full#CD010747-tbl-0004"><b>Summary of findings 4</b> IM injection compared to IA injection for critical lower limb ischaemia</a> </p> <section id="CD010747-sec-0091"> <h4 class="title">Primary outcomes</h4> <section id="CD010747-sec-0092"> <h5 class="title">1. All‐cause mortality</h5> <p>Three of the nine included RCTs involving a total of 100 CLI participants reported a total of nine deaths (9%) during the study follow‐up period (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>). None of the included studies reported all‐cause mortality according to treatment group. Causes of death were heart failure in four participants (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>), myocardial infarction in two participants (<a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>), and respiratory tract infection in three participants (<a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>). </p> </section> <section id="CD010747-sec-0093"> <h5 class="title">2. Amputation rate</h5> <section id="CD010747-sec-0094"> <h6 class="title">Comparison 1: BM‐MNCs vs mPBSCs</h6> <p>A single study in this comparison showed no clear difference in amputation rates between the two groups (risk ratio (RR) 1.54, 95% confidence interval (CI) 0.45 to 5.24; 150 participants; low‐quality evidence) (<a href="./references#CD010747-fig-0004" title="">Analysis 1.1</a>) (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>). </p> </section> <section id="CD010747-sec-0095"> <h6 class="title">Comparison 2: BM‐MNCs vs BM‐MSCs</h6> <p>Only a single study (37 participants) performed this comparison, reporting zero cases of amputation in both groups (<a href="./references#CD010747-fig-0013" title="">Analysis 2.1</a>) (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> </section> <section id="CD010747-sec-0096"> <h6 class="title">Comparison 3: high cell dose vs low cell dose</h6> <p>The only study in this comparison showed no clear difference in amputation rates between high cell dose and low cell dose groups (RR 3.21, 95% CI 0.87 to 11.90; 16 participants; very low‐quality evidence) (<a href="./references#CD010747-fig-0020" title="">Analysis 3.1</a>) (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </section> <section id="CD010747-sec-0097"> <h6 class="title">Comparison 4: route of implantation: IM vs IA</h6> <p>Three studies involving a total of 95 CLI participants showed no clear difference in amputation rates between the different routes of cell implantation (RR 0.80, 95% CI 0.54 to 1.18; 95 participants; I² = 48%; low‐quality evidence) (<a href="./references#CD010747-fig-0021" title="">Analysis 4.1</a>) (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>). </p> </section> </section> <section id="CD010747-sec-0098"> <h5 class="title">3. Wound/ulcer healing</h5> <p>Included studies reported wound/ulcer healing as the number of participants with improvement or healing of ulcers or change in ulcer size. </p> <section id="CD010747-sec-0099"> <h6 class="title">Comparison 1: BM‐MNCs vs mPBSCs</h6> <p>The single study in this comparison showed no clear difference in numbers of participants with healing ulcers between the two treatment groups (RR 0.89, 95% CI 0.44 to 1.83; 49 participants; low‐quality evidence) (<a href="./references#CD010747-fig-0005" title="">Analysis 1.2</a>) (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>). </p> <p>For the change in ulcer size outcome, <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a> reported no clear change between the two treatment groups (mean difference (MD) ‐1.06 cm², 95% CI ‐5.35 to 3.23; 49 participants) (<a href="./references#CD010747-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD010747-sec-0100"> <h6 class="title">Comparison 2: BM‐MNCs vs BM‐MSCs</h6> <p>The only study in this comparison showed that the number of participants with healing ulcers was higher in the BM‐MSC group than in the BM‐MNC group (RR 2.00, 95% CI 1.02 to 3.92; 22 participants; P = 0.04; moderate‐quality evidence) (<a href="./references#CD010747-fig-0014" title="">Analysis 2.2</a>) (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> </section> <section id="CD010747-sec-0101"> <h6 class="title">Comparison 3: high cell dose vs low cell dose</h6> <p>The single study in this comparison did not report on this outcome (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </section> <section id="CD010747-sec-0102"> <h6 class="title">Comparison 4: route of implantation: IM vs IA</h6> <p>A single included study showed no clear difference in the numbers of participants with healing ulcers between IM and IA cell implantation (RR 1.13, 95% CI 0.73 to 1.76; 41 participants; low‐quality evidence) (<a href="./references#CD010747-fig-0022" title="">Analysis 4.2</a>) (<a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>). </p> </section> </section> </section> <section id="CD010747-sec-0103"> <h4 class="title">Secondary outcomes</h4> <section id="CD010747-sec-0104"> <h5 class="title">1. Reduction in rest pain</h5> <p>Reduction in rest pain is reported either as the number of participants with reduction in rest pain score or as a mean reduction in rest pain score. </p> <section id="CD010747-sec-0105"> <h6 class="title">Comparison 1: BM‐MNCs vs mPBSCs</h6> <p>Two studies involving a total of 202 CLI participants reported rest pain score of any magnitude at three to six months from baseline for participants treated with either BM‐MNCs or mPBSCs (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>). We could not pool data obtained from <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a> with data from <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a> because <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a> reported rest pain data as mean reduction in rest pain score, but <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a> reported data as the number of participants with reduction in rest pain. <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a> showed no clear difference in pain relief between the two treatment groups (RR 0.99, 95% CI 0.93 to 1.06; 104 participants; moderate‐quality evidence) (<a href="./references#CD010747-fig-0007" title="">Analysis 1.4</a>). In contrast, <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a> showed a reduction in rest pain score 12 weeks after mPBSC injection (MD ‐0.57, 95% CI ‐0.90 to ‐0.24; 150 participants) (<a href="./references#CD010747-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD010747-sec-0106"> <h6 class="title">Comparison 2: BM‐MNCs vs BM‐MSCs</h6> <p>The only study in this comparison did not show a difference in pain relief in ischaemic limbs between the two groups (MD 0.00, 95% CI ‐0.61 to 0.61; 37 participants; moderate‐quality evidence) (<a href="./references#CD010747-fig-0015" title="">Analysis 2.3</a>) (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> </section> <section id="CD010747-sec-0107"> <h6 class="title">Comparison 3: high cell dose vs low cell dose</h6> <p><a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a> did not report on this outcome. </p> </section> <section id="CD010747-sec-0108"> <h6 class="title">Comparison 4: route of implantation: IM vs IA</h6> <p>A single included study showed no difference in the numbers of participants with reduction in rest pain between IA and IM routes of implantation (RR 1.22, 95% CI 0.91 to 1.64; 32 participants; low‐quality evidence) (<a href="./references#CD010747-fig-0023" title="">Analysis 4.3</a>) (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>). </p> </section> </section> <section id="CD010747-sec-0109"> <h5 class="title">2. Improvement in lower limb perfusion as measured by improvement in ankle‐brachial pressure index (ABI) </h5> <p><a href="./references#CD010747-bbs2-0149" title="DormandyJA , RutherfordRB . Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter‐Society Consensus (TASC). Journal of Vascular Surgery2000;31(1 Pt 2):S1‐S296. [PUBMED: 10666287] ">Dormandy 2000</a> defined improvement in ABI as an increase in ABI values greater than 0.1 in the treated limb from baseline value according to the standard assessment of interventional therapy for PAD. Pooled estimates of ABI values extracted from individual RCTs are presented as RRs of the number of participants with improvement in ABI or MD of the ABI score after intervention from baseline. </p> <section id="CD010747-sec-0110"> <h6 class="title">Comparison 1: BM‐MNCs vs mPBSCs</h6> <p>Two studies reported change in ABI at 4 and 12 weeks from baseline in 202 participants treated with either BM‐MNCs or mPBSCs (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>). Pooled analysis was not feasible owing to differences in units used to report a change in ABI in these studies. <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a> showed that improvement in ABI was better in the mPBSC group than in the BM‐MNC group (MD ‐0.06, 95% CI ‐0.09 to ‐0.03; 150 participants; <a href="./references#CD010747-fig-0010" title="">Analysis 1.7</a>), and <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a> showed no improvement in ABI between the two treatment groups (RR 1.00, 95% CI 0.71 to 1.40; 104 participants; moderate‐quality evidence; <a href="./references#CD010747-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD010747-sec-0111"> <h6 class="title">Comparison 2: BM‐MNCs vs BM‐MSCs</h6> <p>Only a single study performed this comparison. <a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a> showed that participants who received BM‐MSCs had higher ABI than those given BM‐MNCs (MD 0.05, 95% CI 0.01 to 0.09; 37 participants; low‐quality evidence) (<a href="./references#CD010747-fig-0016" title="">Analysis 2.4</a>). </p> </section> <section id="CD010747-sec-0112"> <h6 class="title">Comparison 3: high cell dose vs low cell dose</h6> <p><a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a> did not report on this outcome. </p> </section> <section id="CD010747-sec-0113"> <h6 class="title">Comparison 4: route of implantation: IM vs IA</h6> <p><a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a> did not show a clear difference in the number of participants with improvement in ABI following treatment via the IA or IM route of implantation (RR 0.93, 95% CI 0.43 to 2.00; 35 participants; very low‐quality evidence) (<a href="./references#CD010747-fig-0024" title="">Analysis 4.4</a>). </p> <p><a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>, who reported ABI score, did not show a clear difference in ABI scores between different routes of implantation (MD ‐0.17, 95% CI ‐0.37 to 0.03; 27 participants) (<a href="./references#CD010747-fig-0025" title="">Analysis 4.5</a>). </p> </section> </section> <section id="CD010747-sec-0114"> <h5 class="title">3. Improvement in lower limb perfusion as measured by improvement in transcutaneous oxygen tension (TcO₂) </h5> <p>We have presented pooled estimates of TcO₂ values extracted from individual RCTs as RR of the number of participants with improvement in TcO₂ readings or mean difference (MD) in the TcO₂ reading from baseline. </p> <section id="CD010747-sec-0115"> <h6 class="title">Comparison 1: BM‐MNCs vs mPBSCs</h6> <p>One study involving a total of 150 CLI participants reported an increase in TcO₂ readings in the mPBSC group compared with the BM‐MNC group (MD 1.70 mmHg, 95% CI 0.41 to 2.99; 150 participants; low‐quality evidence) (<a href="./references#CD010747-fig-0011" title="">Analysis 1.8</a>) (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>). </p> </section> <section id="CD010747-sec-0116"> <h6 class="title">Comparison 2: BM‐MNCs vs BM‐MSCs</h6> <p>Only a single study performed this comparison (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). This study showed an increase in TcO₂ readings in the BM‐MSC group compared with the BM‐MNC group (MD 8.00 mmHg, 95% CI 3.46 to 12.54; 37 participants; low‐quality evidence) (<a href="./references#CD010747-fig-0017" title="">Analysis 2.5</a>). </p> </section> <section id="CD010747-sec-0117"> <h6 class="title">Comparison 3: high cell dose vs low cell dose</h6> <p><a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a> did not report on this outcome. </p> </section> <section id="CD010747-sec-0118"> <h6 class="title">Comparison 4: route of implantation: IM vs IA</h6> <p>Pooled analysis of two studies did not show a difference in the numbers of participants with improved TcO₂ readings between IM and IA cell implantation groups (RR 1.22, 95% CI 0.86 to 1.72; 62 participants; I² = 0%; very low‐quality evidence) (<a href="./references#CD010747-fig-0026" title="">Analysis 4.6</a>) (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>). </p> </section> </section> <section id="CD010747-sec-0119"> <h5 class="title">4. Improvement in ischaemic symptoms as assessed by improvement in pain‐free walking distance (PFWD) and pain‐free walking time (PFWT) </h5> <p>Only two studies reported PFWD or PFWT (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> <section id="CD010747-sec-0120"> <h6 class="title">Comparison 1: BM‐MNCs vs mPBSCs</h6> <p>The only study that performed this comparison did not show a clear difference in mean PFWD between the two treatment groups (MD 33.05 metres, 95% CI ‐37.69 min to 103.79 min; 150 participants) (<a href="./references#CD010747-fig-0012" title="">Analysis 1.9</a>) (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>). </p> </section> <section id="CD010747-sec-0121"> <h6 class="title">Comparison 2: BM‐MNCs vs BM‐MSCs</h6> <p>The only study that performed this comparison did not show a clear difference in mean PFWT between the two treatment groups (MD 0.6 min, 95% CI ‐0.01 min to 1.21 min; 37 participants) (<a href="./references#CD010747-fig-0018" title="">Analysis 2.6</a>) (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> </section> </section> <section id="CD010747-sec-0122"> <h5 class="title">5. Improvement in vascularity and blood supply to the ischaemic limb as measured by collateral vessel formation </h5> <p>CLI participants in the included studies were subjected to angiography before and at three to six months after cell implantation to identify new collateral vessel formation in treated and control limbs. </p> <section id="CD010747-sec-0123"> <h6 class="title">Comparison 1: BM‐MNCs vs PBSCs</h6> <p><a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a> and <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a> did not report on this outcome. </p> </section> <section id="CD010747-sec-0124"> <h6 class="title">Comparison 2: BM‐MNCs vs BM‐MSCs</h6> <p>The only study that performed this comparison showed a higher number of participants with new collaterals at 24 weeks in the BM‐MSC‐treated group than in the BM‐MNC‐treated group (RR 1.98, 95% CI 1.12 to 3.49; 37 participants) (<a href="./references#CD010747-fig-0019" title="">Analysis 2.7</a>) (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> </section> <section id="CD010747-sec-0125"> <h6 class="title">Comparison 3: high cell dose vs low cell dose</h6> <p><a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a> did not report on this outcome. </p> </section> <section id="CD010747-sec-0126"> <h6 class="title">Comparison 4: route of implantation: IM vs IA</h6> <p>The only study in this comparison showed no difference in the numbers of participants with collateral formation between different routes of cell implantation (RR 0.91, 95% CI 0.40 to 2.11; 15 participants) (<a href="./references#CD010747-fig-0027" title="">Analysis 4.7</a>) (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>). </p> </section> </section> <section id="CD010747-sec-0127"> <h5 class="title">6. Adverse events and safety</h5> <p>None of the included RCTs reported adverse events for the intervention and control groups separately, hence we were unable to undertake meta‐analyses for this outcome. Nonetheless, most of the studies (six out of seven RCTs) reported that in general, cell‐based therapy was well tolerated without significant and severe adverse events related to bone marrow aspiration and cell implantation into the affected limb. The individual studies reported no infection and no biochemical or immunological reactions among participants who had received cell implantation. However, reported data on the long‐term safety of cell‐based therapy were lacking. </p> <p>As pooled analyses were not possible for this outcome, we describe adverse effects reported by the individual studies according to the following comparisons. </p> <section id="CD010747-sec-0128"> <h6 class="title">Comparison 1: BM‐MNCs vs mPBSCs</h6> <p>One study reported that cell implantation in both groups did not induce local inflammatory reaction or oedema of the lower limbs (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>). Study results show that the most common adverse events during G‐CSF mobilisation in mPBSC were bone pain (13.2%; 10/76) and lassitude (5.3%; 4/76), but no participants were required to withdraw from the mobilisation procedure or required special treatment. No implantation‐related complications were observed through electrocardiograms, liver and kidney function tests, and urine tests during the 12‐week follow‐up period. Researchers followed up 43 participants in the mPBSC group and 41 in the BM‐MNC group over a 12‐month period and noted no implantation‐related complications during this time. Another study reported no significant adverse effects in all participants (<a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>). </p> </section> <section id="CD010747-sec-0129"> <h6 class="title">Comparison 2: BM‐MNCs vs BM‐MSCs</h6> <p>One of the three RCTs that used BM‐MSCs reported detailed data on the safety profile of cell‐based treatment (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). Study authors observed minimal bleeding at the posterior iliac crest after bone marrow aspiration in one and two participants in the BM‐MSC and BM‐MNC groups, respectively. In addition, three limbs in the BM‐MSC group and two in the BM‐MNC group were reported as painful in the short term after cell implantation (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> </section> <section id="CD010747-sec-0130"> <h6 class="title">Comparison 3: high cell dose vs low cell dose</h6> <p>One RCT reported 60 serious adverse events (SAEs) in 22 participants (78.6%), 59 of which occurred after IM cell implantation, and one during G‐CSF mobilisation (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). Only two SAEs were considered possibly study‐related: one participant developed moderate hypotension and another experienced worsening ischaemia of the implanted limb. One participant in the control (placebo) group developed acute myocardial infarction four to five months after randomisation. Adverse events did not necessitate withdrawal of participants from the study. </p> </section> <section id="CD010747-sec-0131"> <h6 class="title">Comparison 4: route of implantation: IM vs IA</h6> <p>Individual studies reported no adverse events related to implantation of cells and no difference in the occurrence of adverse events among participants who received cell treatment via IM and IA routes, indicating that both routes of cell delivery were safe and feasible (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>). Eight deaths due to cardiovascular and respiratory events were not related to cell implantation. Meta‐analysis was not feasible, as these studies did not provide comparative adverse events data for the different routes of cell implantation. </p> </section> </section> </section> <section id="CD010747-sec-0132"> <h4 class="title">Subgroup analysis</h4> <p>We were unable to perform any subgroup analyses for each outcome describing participants with different severity and aetiology of CLI, participants with or without significant comorbidity, and participants of different age groups, gender, and ethnicity, as we could not obtain separate data according to these pre‐specified criteria from the included studies under each comparison. </p> </section> <section id="CD010747-sec-0133"> <h4 class="title">Sensitivity analysis</h4> <p>We were unable to perform sensitivity analyses for significant dropout rates and significant methodological issues identified in the assessment of risk of bias, as insufficient data were available. </p> <p>We conducted sensitivity analyses for the relevant outcomes to identify if pooled estimates of outcomes would change with inclusion and exclusion of studies in which limbs rather than participants were used as units of analysis. </p> <section id="CD010747-sec-0134"> <h5 class="title">Outcome: amputation rate</h5> <p>Comparison: IM versus IA implantation: results show no substantial change after one study that used limbs as the unit of analysis ‐ <a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a> ‐ was excluded (before exclusion: RR 0.80, 95% CI 0.54 to 1.18; three RCTs, 95 participants; I² = 48%; after exclusion: RR 0.86, 95% CI 0.59 to 1.26; two RCTs, 60 participants; I² = 61%) (<a href="./references#CD010747-fig-0021" title="">Analysis 4.1</a>). </p> </section> <section id="CD010747-sec-0135"> <h5 class="title">Outcome: improvement in lower limb perfusion as measured by improvement in transcutaneous oxygen tension (TcO₂) </h5> <section id="CD010747-sec-0136"> <h6 class="title">Number of participants with improved TcO₂ reading</h6> <p>Comparison: IM versus IA implantation: results show no substantial change after one study that used limbs as the unit of analysis ‐ <a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a> ‐ was excluded (before exclusion: RR 1.22, 95% CI 0.86 to 1.72; two RCTs, 62 participants; I² = 0%; after exclusion: RR 1.19, 95% CI 0.63 to 2.26; one RCT, 27 participants) (<a href="./references#CD010747-fig-0026" title="">Analysis 4.6</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010747-sec-0137" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010747-sec-0137"></div> <section id="CD010747-sec-0138"> <h3 class="title" id="CD010747-sec-0138">Summary of main results</h3> <p>The main findings of the review show no clear differences in almost all comparisons between different cell sources and implantation regimens for the major clinical outcomes of all‐cause mortality, amputation rate, improvement in rest pain, number of participants with healing ulcer, and improvement in ankle‐brachial index (ABI). However, underpowered analyses for all comparisons precluded any clear and firm conclusions. </p> <p>Of note, most of the included trials were not specifically designed to compare adverse events or long‐term safety between the various sources and types of cell‐based regimens. Hence review authors found a paucity of comparative adverse event data between treatment groups, confounded by short follow‐up duration. Nonetheless, the randomised controlled trials (RCTs) included in this review support the short–term safety and feasibility of autologous implantation of stem cells obtained from bone marrow or peripheral blood into ischaemic limbs. The most common adverse events following bone marrow harvesting were short‐term episodes of slight pain, bleeding, and haematoma at the bone marrow aspiration site that did not require specific intervention. Apart from granulocyte colony‐stimulating factor (G‐CSF)‐induced transient bone pain that did not require special treatment, mobilisation of mobilised peripheral blood stem cells (mPBSCs) was well tolerated. Researchers reported no local adverse reactions at the cell implantation site. Individual studies reported no infection and no biochemical or immunological reactions among participants following cell implantation. </p> <p>Although each individual RCT described no difference in the occurrence of adverse events related to route of implantation and cell dose, the small sample size and lack of comparative data in these studies precluded any convincing conclusions on the overall safety of cell‐based therapy. In addition, evidence on the long‐term safety profile of different types of cell‐based products, namely, bone marrow‐mononuclear cells (BM‐MNCs), bone marrow‐mesenchymal stem cells (BM‐MSCs), mPBSCs, and peripheral blood‐mononuclear cells (PB‐MNCs), is lacking. </p> </section> <section id="CD010747-sec-0139"> <h3 class="title" id="CD010747-sec-0139">Overall completeness and applicability of evidence</h3> <p>In terms of the applicability of our review, the current mainstay of treatment for critical limb ischaemia (CLI) has been endovascular or surgical revascularisation and pharmacological therapy. However, the presence of significant comorbidities and distal vessel disease renders many patients unsuitable for revascularisation, often resulting in amputation (<a href="./references#CD010747-bbs2-0163" title="LiewA , BhattacharyaV , ShawJ , StansbyG . Cell therapy for critical limb ischemia: a meta‐analysis of randomized controlled trials. Angiology2016;67(5):444‐555. [PUBMED: 26195561] ">Liew 2016</a>). Exploring new strategies for revascularisation therapy is thus of major importance. The most recent published clinical practice guideline did not include cell‐based therapy as one of the limb salvage treatment modalities (<a href="./references#CD010747-bbs2-0168" title="National Guideline Clearinghouse (NGC). Lower limb peripheral arterial disease: diagnosis and management. National Institute for Health and Clinical Excellence (NICE) 2012 Aug. 28, issue Clinical guideline no. 147. ">NGC 2012</a>). Currently, cell‐based therapy is at a preliminary stage of use or is being utilised mainly in research. </p> <p>Each RCT included in this review contained a small sample size ranging from 16 to 150 participants and a relatively short follow‐up period (range 1 to 12 months). The number of included RCTs was very small (seven), and comparisons for each outcome included only one to three studies. </p> <p>Moreover, substantial variation in patient selection processes was evident, even within the relatively small population group (<a href="./references#CD010747-bbs2-0179" title="SultanS , HynesN . Critical appraisal of stem cell therapy in peripheral arterial disease: do current scientific breakthroughs offer true promise or false hope?. Journal of Biomedical Science and Engineering2014;7:75‐85. ">Sultan 2014</a>). In particular, the criteria used to define 'CLI' and 'no‐option' patients lacked uniformity. Trials examined varying degrees of lower limb ischaemia, ranging from intermittent claudication to non‐healing ulcers and gangrene. Differences in the severity of peripheral arterial disease (PAD) may partly explain the differences in changes in blood flow parameters between these studies. The review includes a range of aetiologies for CLI, namely, atherosclerosis, Buerger's disease, acute embolism, and others. However, subanalysis for outcomes according to severity and aetiology of CLI was not possible, as individual RCTs did not provide such data. Risk factors such as diabetes mellitus and smoking that are known to cause worsening and progression of lower limb ischaemia were inhomogeneous between the included studies. For example, one RCT included only diabetic patients (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>), and another RCT excluded patients with poorly controlled diabetes mellitus, or those with proliferative diabetic retinopathy (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>). </p> <p>Lack of uniformity in assessment, analysis, and reporting of efficacy endpoints between the individual RCTs precluded combining efficacy data for meta‐analysis, so much so that the findings of this systematic review are based in part on results derived from one or two studies. For example, there were differences in the methods and units used to calculate, document, and report objective outcomes such as ABI and ulcer healing. Investigators used several different scoring systems to measure and interpret subjective outcomes including patient‐perceived rest pain and pain‐free walking distance (PFWD) and pain‐free walking time (PFWT) in individual RCTs. Moreover, the timing of assessment of outcomes varied between studies. These important variations in efficacy data between studies resulted in insufficient data that could be pooled for meta‐analysis. This was particularly important for comparisons performed with low number of patients in each arm. </p> <p>The present systematic review is not able to demonstrate differences in efficacy and safety between the various sources and types of cell‐based products for the following reasons. Most published trials on this topic compared cell‐based treatment versus conventional, non‐cell‐based therapy. Our search revealed limited published RCTs that performed head‐to‐head comparisons between cells derived from different sources, prepared via different processing protocols, and administered through different doses and routes. We analysed two RCTs comparing BM‐MNCs versus mPBSCs (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>), as well as one RCT comparing BM‐MNCs versus BM‐MSCs (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). For the comparison BM‐MNCs versus mPBSCs, meta‐analysis was not feasible because of differences in the units used to report outcomes between the two cell treatment groups. </p> <p>Limited evidence suggests clear differences in any clinical outcome whether cells were administered at high or low cell doses. Our analysis based on data from a single study shows no clear difference in amputation rates between patients who received high and low doses of CD34+ cells. However, this finding should be interpreted cautiously because of the small sample size and the phenotype of cells used in this study. This study used mobilised PB CD34+ cells (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>), whereas many studies examining cell therapy for CLI patients had used unselected bone marrow‐derived cells (BM‐MNCs). Of note, different cell sources and phenotypes may contain different proportions of stem cells with angiogeneic potential. </p> <p>Most included trials implanted the cells into the gastrocnemius muscle (intramuscular (IM) route). Only three RCTs involving 100 participants directly compared the efficacy of IM and IA routes of cell administration (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>). Meta‐analysis of these trials failed to show superiority of either route; however, the accuracy of this finding is confounded by the small sample size. </p> <p>All‐cause mortality from three RCTs was 9%. However, in view of baseline high risk factors among CLI patients and the limitations of the individual RCTs included in our review, it is not possible to attribute the cause of death to cell treatment. Of note, all RCTs included in this review reported no significant adverse effects related to cell‐based treatment. However, none of these trials performed head‐to‐head comparison of safety data between treatment groups. Moreover, the long‐term safety of cell‐based therapy could not be determined, as the follow‐up period for most RCTs was relatively short, ranging from one to twelve months. Head‐to‐head comparisons between CLI patients treated with different cell‐based regimens and given long‐term follow‐up are warranted to confirm the safety and durability of the efficacy of cell‐based therapy for these patients. </p> <p>Additionally, the relatively short follow‐up period of the included studies has limited the usefulness of this review in informing practice. </p> </section> <section id="CD010747-sec-0140"> <h3 class="title" id="CD010747-sec-0140">Quality of the evidence</h3> <p>Overall, we noted a mixed quality of evidence for different outcome‐comparison combinations, and we concluded that overall the quality of evidence presented was very low to moderate (<a href="./full#CD010747-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD010747-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010747-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD010747-tbl-0004">summary of findings Table 4</a>). Major factors that led to downgrading of the quality of evidence were risk of bias issues, imprecision, and indirectness of evidence. Major methodological limitations in most studies included unclear randomisation methods and/or allocation concealment, as well as lack of blinding of participants and insufficient outcome data. It is important to note that single studies or small numbers of studies with limited participants contributed to all outcomes, resulting in underpowered analyses with wide 95% confidence intervals. Overall, high‐quality evidence needed to assess the effects of utilisation of a particular source or treatment regimen of cell‐based therapy for CLI in clinical practice is lacking. </p> </section> <section id="CD010747-sec-0141"> <h3 class="title" id="CD010747-sec-0141">Potential biases in the review process</h3> <p>We performed a comprehensive search covering multiple major databases to look for published and unpublished studies in full text or abstract format, and we screened for relevant studies among 4904 citations. We believe that the scope of our search was sufficiently complete. </p> <p>It is possible that we may not have identified still unpublished trials. In particular, small studies reporting negative findings may not have been published as full articles. Moreover, several phase 3 trials are currently ongoing. We identified seven ongoing RCTs (<a href="./references#CD010747-bbs2-0138" title="NCT00311805 . Autologous CD34+ stem cell injection for severe intermittent claudication (leg pain). clinicaltrials.gov/ct2/show/study/NCT00311805 (first received 6 April 2006). ">NCT00311805</a>; <a href="./references#CD010747-bbs2-0139" title="NCT00753025 . Autologous bone marrow for lower extremity ischemia treating. clinicaltrials.gov/ct2/show/study/NCT00753025 (first received 16 September 2008). ">NCT00753025</a>; <a href="./references#CD010747-bbs2-0140" title="NCT01257776 . Human adipose derived mesenchymal stem cells for critical limb ischemia (CLI) in diabetic patients. clinicaltrials.gov/ct2/show/study/NCT01257776 (first received 10 December 2010). ">NCT01257776</a>; <a href="./references#CD010747-bbs2-0141" title="NCT01408381 . Intra‐arterial infusion of autologous bone marrow mononuclear cells in non‐diabetic patients with critical limb ischemia (CLI). clinicaltrials.gov/ct2/show/study/NCT01408381 (first received 3 August 2011). ">NCT01408381</a>; <a href="./references#CD010747-bbs2-0142" title="NCT01446055 . Safety and efficacy study of autologous BM‐MNC processed by two methods for treating patients with chronic limb ischemia. clinicaltrials.gov/ct2/show/study/NCT01446055 (first received 4 October 2011). ">NCT01446055</a>; <a href="./references#CD010747-bbs2-0143" title="NCT01745744 . Application of cell regeneration therapy with mesenchymal stem cells from adipose tissue in critical chronic ischemic syndrome of lower limbs (CLI) in nondiabetic patients. clinicaltrials.gov/ct2/show/study/NCT01745744 (first received 10 December 2012). ">NCT01745744</a>; <a href="./references#CD010747-bbs2-0144" title="NCT02454231 . Monocentric trial: stem cell emergency life threatening limbs arteriopathy (SCELTA). clinicaltrials.gov/ct2/show/NCT02454231 (first received 27 May 2015). ">NCT02454231</a>), and we discovered six clinical trials classified as 'awaiting classification' (<a href="./references#CD010747-bbs2-0132" title="Gurunathan ManiS , RajuR , Kuppu SampathV . Multicentre randomised clinical trial on the role of autologous bone‐marrow aspirate‐concentrate (BMAC)/CD34/(EPC) in non‐reconstructable critically ischaemic limbs. The Vascular Society of Great Britain &amp; Ireland Yearbook 2009. 2009:56. ">Gurunathan 2009</a>; <a href="./references#CD010747-bbs2-0133" title="KorymasovEA , TiuminaOV , AiupovAM , KazantsevAV , RossievVA , MikheevGV , et al. Use of autologous progenitor cells of the bone marrow in treatment of patients with lower‐limb atherosclerosis obliterans. Angiologiia i Sosudistaia Khirurgiia = Angiology and Vascular Surgery2009;15(3):28‐31. [PUBMED: 20092179] ">Korymasov 2009</a>; <a href="./references#CD010747-bbs2-0134" title="MolaviB , ZafarghandiMR , AminizadehE , HosseiniSE , MirzayiH , ArabL , et al. Safety and efficacy of repeated bone marrow mononuclear cell therapy in patients with critical limb ischemia in a pilot randomized controlled trial. Archives of Iranian Medicine2016;19(6):388‐96. [PUBMED: 27293053] NCT01480414 . Side effects of 4 times bone marrow mononuclear transplantation in patients with ischemic lower limb. clinicaltrials.gov/ct2/show/NCT01480414 (first received 28 November 2011). ">Molavi 2016</a>; <a href="./references#CD010747-bbs2-0135" title="NCT00595257 . Feasibility study of autologous bone marrow aspirate concentrate for treatment of CLI. clinicaltrials.gov/ct2/show/study/NCT00595257 (first received 16 January 2008). ">NCT00595257</a>; <a href="./references#CD010747-bbs2-0136" title="NCT00987363 . Intraarterial infusion of autologous bone marrow in diabetic patients with chronic ischemia of lower limbs (CLI) no revascularization. clinicaltrials.gov/ct2/show/study/NCT00987363 (first recieved 30 September 2009). ">NCT00987363</a>; <a href="./references#CD010747-bbs2-0137" title="NCT02993809 . Autologous transplantation of BM‐ECs with platelet‐rich plasma extract for the treatment of critical limb ischemia. clinicaltrials.gov/ct2/show/study/NCT02993809 (first received 15 December 2016). ">NCT02993809</a>), the eligibility criteria of which have yet to be determined. Results of these trials will likely provide efficacy data on cell‐based therapy derived from different sources, administered via different doses, and delivered via different routes. </p> <p>We have excluded a substantial number of clinical trials related to cell‐based treatment for patients with PAD, as most of these were single‐arm studies (42 trials) or were non‐randomised (11 trials). To date, the number of high‐quality trials conducted to compare different types of cell products and treatment regimens is limited. </p> <p>Four RCTs reported their results using limbs rather than patients as the unit of analysis and reported unadjusted results (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>; <a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>; <a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>). We could not obtain sufficient data from the primary studies to adjust for clustering effects, and this might have led to a biased estimate in our results for certain limb‐related outcomes. </p> <p>Researchers described one RCT as a "controlled clinical case analysis", and indicated that patients were randomly assigned to two groups (BM‐MNCs vs mPBSCs) (<a href="./references#CD010747-bbs2-0007" title="ZhangHF , ZhaoZG , ZhangCL , YuanHJ , WangYF . Autologous transplantation of bone marrow stem cells versus peripheral blood stem cells for treatment of diabetic lower limb ischemia: a comparative study in 52 cases. Journal of Clinical Rehabilitative Tissue Engineering Research2009;13(6):1109‐12. ">Zhang 2009</a>). Study authors did not mention the true nature of randomisation. Ideally we would have performed a sensitivity analysis to investigate the effects of randomisation on estimates of outcome; however, this was the only study reporting these effects on outcomes, so we could not perform a sensitivity analysis. </p> <p>Our sensitivity analyses performed to assess the impact of excluding such studies show that in most cases, these exclusions did not change the pooled estimates substantially. </p> <p>We were unable to perform sensitivity analyses for significant or worrisome dropout rates and significant methodological issues identified during assessment of risk of bias, as insufficient data were available. </p> </section> <section id="CD010747-sec-0142"> <h3 class="title" id="CD010747-sec-0142">Agreements and disagreements with other studies or reviews</h3> <p>To date, apart from the current systematic review, limited published meta‐analyses have included RCTs that directly compared the effectiveness of cell‐based products derived from different sources, prepared using different regimens, and delivered via different routes. Most published meta‐analyses compared cell therapy versus conventional treatment (non‐cell‐based therapy) and also included non‐RCTs. Direct comparison of the efficacy of different cell sources and types reported by individual RCTs has yielded inconsistent results. Hence, the efficacy and safety of different cell‐based products remain to be determined. </p> <p>Three previous meta‐analyses involving 510 (twelve RCTs), 276 (seven RCTs), and 373 (seven RCTs) PAD patients, respectively, underlined the promising results of cell‐based therapy compared to conventional therapy (non‐cell‐based therapy) (<a href="./references#CD010747-bbs2-0164" title="LiuFP , DongJJ , SunSJ , GaoWY , ZhangZW , ZhouXJ , et al. Autologous bone marrow stem cell transplantation in critical limb ischemia: a meta‐analysis of randomized controlled trials. Chinese Medical Journal2012;125(23):4296‐300. [PUBMED: 23217403] ">Liu 2012</a>; <a href="./references#CD010747-bbs2-0181" title="TeraaM , SprengersRW , van derGraafY , PetersCE , MollFL , VerhaarMC . Autologous bone marrow‐derived cell therapy in patients with critical limb ischemia: a meta‐analysis of randomized controlled clinical trials. Annals of Surgery2013;258(6):922‐9. [PUBMED: 23426345] ">Teraa 2013</a>; <a href="./references#CD010747-bbs2-0182" title="WenY , MengL , GaoQ . Autologous bone marrow cell therapy for patients with peripheral arterial disease: a meta‐analysis of randomized controlled trials. Expert Opinion on Biological Therapy2011;11(12):1581‐9. [PUBMED: 21973046] ">Wen 2011</a>). In contrast to the current review, these previously published meta‐analyses combined and analysed patients treated with cells from different sources and different types of cells (BM‐MNCs, BM‐MSCs, mPBSCs, Ixmyelocel‐T) and collectively reported them as bone marrow‐derived cell therapy. </p> <p>Two recent meta‐analyses attempted to compare outcomes for patients receiving different cell types versus non‐cell‐based therapy (<a href="./references#CD010747-bbs2-0163" title="LiewA , BhattacharyaV , ShawJ , StansbyG . Cell therapy for critical limb ischemia: a meta‐analysis of randomized controlled trials. Angiology2016;67(5):444‐555. [PUBMED: 26195561] ">Liew 2016</a>; <a href="./references#CD010747-bbs2-0165" title="LiuY , XuY , FangF , ZhangJ , GuoL , WengZ . Therapeutic efficacy of stem cell‐based therapy in peripheral arterial disease: a meta‐analysis. PloS One2015;10(4):e0125032. [PUBMED: 25923119] ">Liu 2015</a>). In <a href="./references#CD010747-bbs2-0165" title="LiuY , XuY , FangF , ZhangJ , GuoL , WengZ . Therapeutic efficacy of stem cell‐based therapy in peripheral arterial disease: a meta‐analysis. PloS One2015;10(4):e0125032. [PUBMED: 25923119] ">Liu 2015</a>, the subgroup analysis based on stem cell sources showed significant improvement in amputation rates, ulcer healing, and ABI in patients implanted with bone marrow‐derived cells or peripheral blood‐derived cells compared to controls. However, in contrast to our review, <a href="./references#CD010747-bbs2-0165" title="LiuY , XuY , FangF , ZhangJ , GuoL , WengZ . Therapeutic efficacy of stem cell‐based therapy in peripheral arterial disease: a meta‐analysis. PloS One2015;10(4):e0125032. [PUBMED: 25923119] ">Liu 2015</a> included non‐randomised studies in its meta‐analysis (<a href="./references#CD010747-bbs2-0022" title="CobellisG , SilvestroniA , LilloS , SicaG , BottiC , MaioneC , et al. Long‐term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplantation2008;42(10):667‐72. [PUBMED: 18695661] ">Cobellis 2008</a>; <a href="./references#CD010747-bbs2-0032" title="DubskyM , JirkovskaA , BemR , FejfarovaV , PagacovaL , SixtaB , et al. Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment. Diabetes/Metabolism Research and Reviews2013;29(5):369‐76. [PUBMED: 23390092] ">Dubsky 2013</a>). Review authors compared clinical outcomes of cell treatment groups versus non‐cell treatment groups and did not perform head‐to‐head comparisons between cells derived from different sources or implanted via different implantation regimens. Furthermore, review authors pooled and analysed outcome data from studies using different types of cells, for example, the bone marrow cell group consisted of patients treated with allogeneic MSCs (<a href="./references#CD010747-bbs2-0043" title="GuptaPK , ChullikanaA , ParakhR , DesaiS , DasA , GottipamulaS , et al. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. Journal of Translational Medicine2013;11:143. [PUBMED: 23758736] ">Gupta 2013</a>), BM‐MNCs (<a href="./references#CD010747-bbs2-0120" title="NCT00282646 . Safety and feasibility study of autologous bone marrow cell transplantation in patients with PAOD. clinicaltrials.gov/ct2/show/study/NCT00282646 (first received 27 January 2006). WalterDH , KrankenbergH , BalzerJO , KalkaC , BaumgartnerI , SchluterM , et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized‐start, placebo‐controlled pilot trial (PROVASA). Circulation. Cardiovascular Interventions2011;4(1):26‐37. [PUBMED: 21205939] ">Walter 2011</a>), and tissue repair cells (<a href="./references#CD010747-bbs2-0106" title="PowellRJ , MarstonWA , BerceliSA , GuzmanR , HenryTD , LongcoreAT , et al. Cellular therapy with Ixmyelocel‐T to treat critical limb ischemia: the randomized, double‐blind, placebo‐controlled RESTORE‐CLI trial. Molecular Therapy2012;20(6):1280‐6. [PUBMED: 22453769] ">Powell 2012</a>), and the peripheral blood cell group consisted of patients treated with VesCell ‐ as in <a href="./references#CD010747-bbs2-0114" title="SzaboGV , KovesdZ , CserepesJ , DaroczyJ , BelkinM , AcsadyG . Peripheral blood‐derived autologous stem cell therapy for the treatment of patients with late‐stage peripheral artery disease ‐ results of the short‐ and long‐term follow‐up. Cytotherapy2013;15(10):1245‐52. [PUBMED: 23993298] ">Szabo 2013</a> ‐ and with mPBSCs (<a href="./references#CD010747-bbs2-0051" title="HuangP , LiS , HanM , XiaoZ , YangR , HanZC . Autologous transplantation of granulocyte colony‐stimulating factor‐mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care2005;28(9):2155‐60. [PUBMED: 16123483] NCT00730561 . Hematopoietic stem cell transplantation for the treatment of limb ischemia and diabetic neuropathy. clinicaltrials.gov/ct2/show/NCT00730561 (first received 8 August 2008). ">Huang 2005</a>; <a href="./references#CD010747-bbs2-0076" title="MohammadzadehL , SamedanifardSH , KeshavarziA , AlimoghaddamK , LarijaniB , GhavamzadehA , et al. Therapeutic outcomes of transplanting autologous granulocyte colony‐stimulating factor‐mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia. Experimental and Clinical Endocrinology &amp; Diabetes2013;121(1):48‐53. [PUBMED: 23329572] ">Mohammadzadeh 2013</a>; <a href="./references#CD010747-bbs2-0099" title="OzturkA , KucukardaliY , TangiF , ErikciA , UzunG , BashekimC , et al. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. Journal of Diabetes and Its Complications2012;26(1):29‐33. [PUBMED: 22240264] ">Ozturk 2012</a>). </p> <p><a href="./references#CD010747-bbs2-0163" title="LiewA , BhattacharyaV , ShawJ , StansbyG . Cell therapy for critical limb ischemia: a meta‐analysis of randomized controlled trials. Angiology2016;67(5):444‐555. [PUBMED: 26195561] ">Liew 2016</a> concluded that patients treated with PB‐MNCs and bone marrow concentrate had a reduced rate of major amputation compared to those given other cell types (i.e. PB‐MNCs, BM‐MSCs, BM‐MNCs). However, in contrast to our analysis, review authors did not perform head‐to‐head comparisons between a particular cell‐based product and another cell‐based product. Furthermore, review authors arrived at their conclusions upon analysing pooled data from studies that used different types of cells, namely, mPBSCs, VesCell (<a href="./references#CD010747-bbs2-0114" title="SzaboGV , KovesdZ , CserepesJ , DaroczyJ , BelkinM , AcsadyG . Peripheral blood‐derived autologous stem cell therapy for the treatment of patients with late‐stage peripheral artery disease ‐ results of the short‐ and long‐term follow‐up. Cytotherapy2013;15(10):1245‐52. [PUBMED: 23993298] ">Szabo 2013</a>), and CD133+ cells (<a href="./references#CD010747-bbs2-0172" title="RavalAN , SchmuckEG , TeferaG , LeitzkeC , ArkCV , HeiD , et al. Bilateral administration of autologous CD133+ cells in ambulatory patients with refractory critical limb ischemia: lessons learned from a pilot randomized, double‐blind, placebo‐controlled trial. Cytotherapy2014;16(12):1720‐32. [PUBMED: 25239491] ">Raval 2014</a>), and they combined and analysed data collectively as PB‐MNCs, while pooling, combining, and analysing collectively as BM‐MSCs allogeneic MSCs (<a href="./references#CD010747-bbs2-0043" title="GuptaPK , ChullikanaA , ParakhR , DesaiS , DasA , GottipamulaS , et al. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. Journal of Translational Medicine2013;11:143. [PUBMED: 23758736] ">Gupta 2013</a>), autologous MSCs (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>), and tissue repair cells (<a href="./references#CD010747-bbs2-0106" title="PowellRJ , MarstonWA , BerceliSA , GuzmanR , HenryTD , LongcoreAT , et al. Cellular therapy with Ixmyelocel‐T to treat critical limb ischemia: the randomized, double‐blind, placebo‐controlled RESTORE‐CLI trial. Molecular Therapy2012;20(6):1280‐6. [PUBMED: 22453769] ">Powell 2012</a>). As with meta‐analysis performed by <a href="./references#CD010747-bbs2-0165" title="LiuY , XuY , FangF , ZhangJ , GuoL , WengZ . Therapeutic efficacy of stem cell‐based therapy in peripheral arterial disease: a meta‐analysis. PloS One2015;10(4):e0125032. [PUBMED: 25923119] ">Liu 2015</a>, differences in the types of cell products used for implantation may have had an important impact on clinical outcomes. </p> <p>A large meta‐analysis involving almost 700 'no‐option' CLI patients from 37 clinical trials comparing the efficacy of BM‐MNC and mPBSC treatment included uncontrolled and non‐randomised trials, rendering the results to have high risk of bias (<a href="./references#CD010747-bbs2-0154" title="FadiniGP , AgostiniC , AvogaroA . Autologous stem cell therapy for peripheral arterial disease meta‐analysis and systematic review of the literature. Atherosclerosis2010;209(1):10‐7. [PUBMED: 19740466] ">Fadini 2010</a>). </p> <p>A Cochrane review that was first published in 2011 and was updated in 2014 includes two small RCTs involving 57 patients comparing IM autologous BM‐MNCs and conventional therapy; the review authors concluded that evidence was insufficient to support intramuscular cell treatment in patients with CLI (<a href="./references#CD010747-bbs2-0167" title="MoazzamiK , MoazzamiB , RoohiA , NedjatS , DolmatovaE . Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD008347.pub3] ">Moazzami 2014</a>). Review authors did not perform a meta‐analysis because the two studies included in that review differed with regards to types of cells implanted (BM‐MNCs vs mPBSCs) and assessment of outcomes (<a href="./references#CD010747-bbs2-0013" title="BarćP , SkóraJ , PupkaA , TurkiewiczD , DorobiszAT , GarcarekJ , et al. Bone‐marrow cells in therapy of critical limb ischaemia of lower extremities ‐ own experience. Acta Angiologica2006;12(4):155‐66. ">Barć 2006</a>; <a href="./references#CD010747-bbs2-0051" title="HuangP , LiS , HanM , XiaoZ , YangR , HanZC . Autologous transplantation of granulocyte colony‐stimulating factor‐mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care2005;28(9):2155‐60. [PUBMED: 16123483] NCT00730561 . Hematopoietic stem cell transplantation for the treatment of limb ischemia and diabetic neuropathy. clinicaltrials.gov/ct2/show/NCT00730561 (first received 8 August 2008). ">Huang 2005</a>); hence the conclusion regarding efficacy of cell treatment compared to conventional treatment was based on data extracted from individual studies with very small sample sizes. </p> <p>Previous meta‐analyses reported that autologous bone marrow‐derived stem cells and G‐CSF‐mobilised PBSCs (mPBSCs) given via IM or IA implantation into the ischaemic limbs appeared to be relatively safe, and side effects were generally mild and transient (<a href="./references#CD010747-bbs2-0163" title="LiewA , BhattacharyaV , ShawJ , StansbyG . Cell therapy for critical limb ischemia: a meta‐analysis of randomized controlled trials. Angiology2016;67(5):444‐555. [PUBMED: 26195561] ">Liew 2016</a>; <a href="./references#CD010747-bbs2-0165" title="LiuY , XuY , FangF , ZhangJ , GuoL , WengZ . Therapeutic efficacy of stem cell‐based therapy in peripheral arterial disease: a meta‐analysis. PloS One2015;10(4):e0125032. [PUBMED: 25923119] ">Liu 2015</a>; <a href="./references#CD010747-bbs2-0180" title="SunX , YingJ , WangY , LiW , WuY , YaoB , et al. Meta‐analysis on autologous stem cell transplantation in the treatment of limb ischemia. International Journal of Clinical and Experimental Medicine2015;8(6):8740‐8. [PUBMED: 26309525] ">Sun 2015</a>; <a href="./references#CD010747-bbs2-0181" title="TeraaM , SprengersRW , van derGraafY , PetersCE , MollFL , VerhaarMC . Autologous bone marrow‐derived cell therapy in patients with critical limb ischemia: a meta‐analysis of randomized controlled clinical trials. Annals of Surgery2013;258(6):922‐9. [PUBMED: 23426345] ">Teraa 2013</a>). Only two RCTs previously reported in detail comparisons of adverse events between cell treatment and non‐cell treatment groups (<a href="./references#CD010747-bbs2-0067" title="LiM , ZhouH , JinX , WangM , ZhangS , XuL . Autologous bone marrow mononuclear cells transplant in patients with critical leg ischemia: preliminary clinical results. Experimental and Clinical Transplantation2013;11(5):435‐9. [PUBMED: 23477421] ">Li 2013</a>; <a href="./references#CD010747-bbs2-0117" title="TeraaM , FledderusJO , RozbehRI , LeguitRJ , VerhaarMC . Bone marrow microvascular and neuropathic alterations in patients with critical limb ischemia. Circulation Research2014;114(2):311‐4. [PUBMED: 24218170] ">Teraa 2014</a>). These studies showed no significant differences in the incidence of adverse events between autologous BM‐MNCs and control interventions. Adverse events most commonly reported in the BM‐MNC group were short‐term episodes of slight pain, bleeding, and haematoma at the bone marrow aspiration site that did not require specific intervention. Adverse events most commonly noted in the mPBSC group were bone pain (13.2%) and lassitude (5.3%) associated with G‐CSF administration, which were transient and did not require discontinuation from G‐CSF therapy and PBSC mobilisation (<a href="./references#CD010747-bbs2-0002" title="HuangPP , YangXF , LiSZ , WenJC , ZhangY , HanZC . Randomised comparison of G‐CSF‐mobilized peripheral blood mononuclear cells versus bone marrow‐mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thrombosis and Haemostasis2007;98(6):1335‐42. [PUBMED: 18064333] ">Huang 2007</a>). In conclusion, most published clinical trials in people with CLI have presented a reassuring short‐term safety profile but sparse data on the long‐term safety of cell‐based therapy. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010747-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010747-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010747-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010747-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BM‐MNCs vs mPBSCs, Outcome 1 Amputation rate." data-id="CD010747-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 BM‐MNCs vs mPBSCs, Outcome 1 Amputation rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BM‐MNCs vs mPBSCs, Outcome 2 Wound/ulcer healing: number of participants with healing ulcers." data-id="CD010747-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 BM‐MNCs vs mPBSCs, Outcome 2 Wound/ulcer healing: number of participants with healing ulcers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BM‐MNCs vs mPBSCs, Outcome 3 Wound/ulcer healing: change in ulcer size." data-id="CD010747-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 BM‐MNCs vs mPBSCs, Outcome 3 Wound/ulcer healing: change in ulcer size.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BM‐MNCs vs mPBSCs, Outcome 4 Reduction in rest pain: number of participants with any reduction in rest pain score." data-id="CD010747-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 BM‐MNCs vs mPBSCs, Outcome 4 Reduction in rest pain: number of participants with any reduction in rest pain score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BM‐MNCs vs mPBSCs, Outcome 5 Reduction in rest pain: rest pain score." data-id="CD010747-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 BM‐MNCs vs mPBSCs, Outcome 5 Reduction in rest pain: rest pain score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BM‐MNCs vs mPBSCs, Outcome 6 Improvement in lower limb perfusion: number of participants with increased ABI." data-id="CD010747-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 BM‐MNCs vs mPBSCs, Outcome 6 Improvement in lower limb perfusion: number of participants with increased ABI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BM‐MNCs vs mPBSCs, Outcome 7 Improvement in lower limb perfusion: ABI score." data-id="CD010747-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 BM‐MNCs vs mPBSCs, Outcome 7 Improvement in lower limb perfusion: ABI score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BM‐MNCs vs mPBSCs, Outcome 8 Improvement in lower limb perfusion: TcO₂ reading in mmHg." data-id="CD010747-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 BM‐MNCs vs mPBSCs, Outcome 8 Improvement in lower limb perfusion: TcO₂ reading in mmHg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BM‐MNCs vs mPBSCs, Outcome 9 Improvement in ischaemic symptoms: PFWD in metres at 12 weeks." data-id="CD010747-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 BM‐MNCs vs mPBSCs, Outcome 9 Improvement in ischaemic symptoms: PFWD in metres at 12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 1 Amputation rate." data-id="CD010747-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 1 Amputation rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 2 Wound/ulcer healing: number of participants with healing ulcers." data-id="CD010747-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 2 Wound/ulcer healing: number of participants with healing ulcers. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 3 Reduction in rest pain: rest pain score." data-id="CD010747-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 3 Reduction in rest pain: rest pain score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 4 Improvement in lower limb perfusion: ABI score." data-id="CD010747-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 4 Improvement in lower limb perfusion: ABI score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 5 Improvement in lower limb perfusion: TcO₂ reading in mmHg." data-id="CD010747-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 5 Improvement in lower limb perfusion: TcO₂ reading in mmHg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 6 Improvement in ischaemic symptoms: PFWT in minutes at 24 weeks." data-id="CD010747-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 6 Improvement in ischaemic symptoms: PFWT in minutes at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 7 Improvement in vascularity and blood supply: number of participants with increase in numbers of collateral vessels." data-id="CD010747-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 BM‐MNCs vs BM‐MSCs, Outcome 7 Improvement in vascularity and blood supply: number of participants with increase in numbers of collateral vessels. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Low cell dose vs high cell dose, Outcome 1 Amputation rate." data-id="CD010747-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Low cell dose vs high cell dose, Outcome 1 Amputation rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Route of injection: IM injection vs IA injection, Outcome 1 Amputation rate." data-id="CD010747-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Route of injection: IM injection vs IA injection, Outcome 1 Amputation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Route of injection: IM injection vs IA injection, Outcome 2 Wound/ulcer healing: number of participants with healing ulcer." data-id="CD010747-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Route of injection: IM injection vs IA injection, Outcome 2 Wound/ulcer healing: number of participants with healing ulcer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Route of injection: IM injection vs IA injection, Outcome 3 Reduction in rest pain: number of participants with reduction in rest pain score." data-id="CD010747-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Route of injection: IM injection vs IA injection, Outcome 3 Reduction in rest pain: number of participants with reduction in rest pain score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Route of injection: IM injection vs IA injection, Outcome 4 Improvement in lower limb perfusion: number of participants with increased ABI." data-id="CD010747-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Route of injection: IM injection vs IA injection, Outcome 4 Improvement in lower limb perfusion: number of participants with increased ABI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Route of injection: IM injection vs IA injection, Outcome 5 Improvement in lower limb perfusion: ABI score." data-id="CD010747-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Route of injection: IM injection vs IA injection, Outcome 5 Improvement in lower limb perfusion: ABI score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Route of injection: IM injection vs IA injection, Outcome 6 Improvement in lower limb perfusion: number of participants with improved TcO₂ reading." data-id="CD010747-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Route of injection: IM injection vs IA injection, Outcome 6 Improvement in lower limb perfusion: number of participants with improved TcO₂ reading. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010747-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/urn:x-wiley:14651858:media:CD010747:CD010747-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_t/tCD010747-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Route of injection: IM injection vs IA injection, Outcome 7 Improvement in vascularity and blood supply: number of participants with increase in numbers of collateral vessels." data-id="CD010747-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Route of injection: IM injection vs IA injection, Outcome 7 Improvement in vascularity and blood supply: number of participants with increase in numbers of collateral vessels. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/media/CDSR/CD010747/image_n/nCD010747-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010747-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">BM‐MNCs compared to mPBSCs for critical lower limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Is BM‐MNC implantation more effective than mPBSC implantation for reducing all‐cause mortality, amputation rate, number of participants with any reduction in rest pain score, and number of healing ulcers and for improving lower limb perfusion in people with critical lower limb ischaemia?</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with critical lower limb ischaemia </p> <p><b>Setting:</b> hospital </p> <p><b>Intervention:</b> BM‐MNCs </p> <p><b>Comparison:</b> mPBSCs </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mPBSCs</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with BM‐MNCs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality</p> <p>Assessed during in‐patient stay</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths were reported by the 2 studies in this comparison (<a href="https://archie.cochrane.org/sections/documents/view?version=z1805300810164174096369342618414%26format=REVMAN#STD-Huang-2007" target="_blank">Huang 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1805300810164174096369342618414%26format=REVMAN#STD-Zhang-2009" target="_blank">Zhang 2009</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Amputation rate</p> <p>Assessed during in‐patient stay</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.54</p> <p>(0.45 to 5.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>150</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/> (24 to 276) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000</p> <p>(24 to 276)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Wound/ulcer healing: number of participants with healing ulcers</p> <p>Assessed during in‐patient stay</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.89</p> <p>(0.44 to 1.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>49</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>407 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>363 per 1000</p> <p>(179 to 746)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>407 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>363 per 1000</p> <p>(179 to 746)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Reduction in rest pain: number of participants with any reduction in rest pain score</p> <p>Assessed during in‐patient stay</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.99<br/> (0.93 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>977 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>968 per 1000</p> <p>(909 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>977 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>968 per 1000<br/> (909 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Improvement in lower limb perfusion: number of participants with increased ABI</p> <p>Assessed at 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.00<br/> (0.71 to 1.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000<br/> (403 to 795) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000<br/> (369 to 744) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in lower limb perfusion: TcO₂ reading in mmHg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean TcO₂ reading in mmHg was 4.68.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean TcO₂ reading in the intervention group was 1.7 mmHg more (0.41 more to 2.99 more).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The study included in this comparison reported the TcO₂ reading in mmHg, not the number of participants with improvement in lower limb perfusion, which was our preferred outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>** We took the median control group event rate for the outcome as "moderate risk".</b> </p> <p>ABI: ankle‐brachial index; BM‐MNCs: bone marrow‐mononuclear cells; CI: confidence interval; mPBSCs: mobilised peripheral blood stem cells; RCT: randomised controlled trial; RR: risk ratio; TcO₂: transcutaneous oxygen tension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different </p> <p><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect </p> <p><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The single included study had unclear risk of selection bias and high risk of performance bias (patients and personnel were not blinded). Quality of evidence was downgraded by one level.<br/> <sup>b</sup>The 95% CI is wide, as it ranges from substantial benefits favouring BM‐MNCs to substantial benefits favouring mPBSCs. Quality of evidence was downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">BM‐MNCs compared to mPBSCs for critical lower limb ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010747-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">BM‐MNCs compared to BM‐MSCs for critical lower limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Is BM‐MNC implantation more effective than BM‐MSC implantation for reducing all‐cause mortality, amputation rate, number of participants with any reduction in rest pain score, and number of healing ulcers and for improving lower limb perfusion in patients with critical lower limb ischaemia?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical lower limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> BM‐MNCs<br/> <b>Comparison:</b> BM‐MSCs </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with BM‐MSCs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with BM‐MNCs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Assessed during in‐patient stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths were reported by the single study included in this comparison (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amputation rate</p> <p>Assessed during in‐patient stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No amputations were reported by the single study included in this comparison (<a href="./references#CD010747-bbs2-0005" title="LuD , ChenB , LiangZ , DengW , JiangY , LiS , et al. Comparison of bone marrow mesenchymal stem cells with bone marrow‐derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double‐blind, randomized, controlled trial. Diabetes Research and Clinical Practice2011;92(1):26‐36. [PUBMED: 21216483] ">Lu 2011</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Wound/ulcer healing: number of participants with healing ulcers</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 2.00<br/> (1.02 to 3.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>909 per 1000<br/> (464 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Moderate**</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>909 per 1000<br/> (464 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduction in rest pain: rest pain score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean rest pain score was 1.4.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean rest pain score in the intervention group was similar (0) (0.61 fewer to 0.61 more). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study included in this comparison reported the rest pain score, not the number of participants with improved rest pain, which was our preferred outcome. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in lower limb perfusion: ABI score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ABI score was 0.12.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ABI score in the intervention group was 0.05 more (0.01 more to 0.09 more).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study included in this comparison reported the ABI score, not the number of participants with improvement in lower limb perfusion, which was our preferred outcome. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in lower limb perfusion: TcO₂ reading in mmHg</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TcO₂ reading in mmHg was 16.4.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TcO₂ reading in the intervention group was 8 mmHg more (3.46 more to 12.54 more).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study included in this comparison reported the TcO₂ reading in mmHg, not the number of participants with improvement in lower limb perfusion, which was our preferred outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>** We took the median control group event rate for the outcome as "moderate risk".</b><br/> ABI: ankle‐brachial index; BM‐MNCs: bone marrow mononuclear cells; BM‐MSCs: bone marrow mesenchymal stem cells; CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; TcO₂: transcutaneous oxygen tension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The effect estimate of a single small study ranges from slight benefit to substantial benefit favouring BM‐MSCs. Quality of evidence was downgraded by one level.<br/> <sup>b</sup>The effect estimate of a single small study ranges from substantial benefit favouring BM‐MNCs to substantial benefit favouring BM‐MSCs. Quality of evidence was downgraded by one level.<br/> <sup>c</sup>ABI score is not a clinical outcome, and its correlation with clinical symptoms and functions is unclear. Quality of evidence was downgraded by one level.<br/> <sup>d</sup>The effect estimate of a single small study ranges from slight to substantial benefit for the intervention group in terms of the outcome measured (ABI score and TcO₂ reading, respectively). Quality of evidence was downgraded by one level for each outcome concerned.<br/> <sup>e</sup>TcO₂ reading is not a clinical outcome, and its correlation with clinical symptoms and functions is unclear. Quality of evidence was downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">BM‐MNCs compared to BM‐MSCs for critical lower limb ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010747-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High cell dose compared to low cell dose for critical lower limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Is high cell dose more effective than low cell dose for reducing all‐cause mortality, amputation rate, number of participants with any reduction in rest pain score, and number of healing ulcers and for improving lower limb perfusion in patients with critical lower limb ischaemia?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical lower limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> high cell dose<br/> <b>Comparison:</b> low cell dose </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low cell dose</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with high cell dose</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Assessed during in‐patient stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths were reported by the single RCT included in this comparison (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Amputation rate</p> <p>Assessed during in‐patient stay</p> <p>(<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 3.21 (0.87 to 11.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>16 (1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>713 per 1000 (193 to 1000)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>222 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>713 per 1000 (193 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wound ulcer healing</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported by the single RCT included in this comparison (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reduction in rest pain</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported by the single RCT included in this comparison (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in lower limb perfusion: ABI</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported by the single RCT included in this comparison (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement in lower limb perfusion: TcO₂</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported by the single RCT included in this comparison (<a href="./references#CD010747-bbs2-0004" title="LosordoDW , KibbeMR , MendelsohnF , MarstonW , DriverVR , SharafuddinM , et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circulation. Cardiovascular Interventions2012;5(6):821‐30. [PUBMED: 23192920] ">Losordo 2012</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>** We took the median control group event rate for the outcome as "moderate risk".</b><br/> ABI: ankle‐brachial index; CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; TcO₂: transcutaneous oxygen tension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The 95% CI of the effect estimate is extremely wide, covering both sides of the no‐effect line. Quality of evidence was downgraded by two levels on the basis of imprecision.<br/> <sup>b</sup>The single included study had unclear risk of selection bias and high risk of selection bias and unclear risk of performance and detection biases, attrition bias, and reporting bias. Quality of evidence was downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High cell dose compared to low cell dose for critical lower limb ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010747-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">IM injection compared to IA injection for critical lower limb ischaemia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Is IM cell implantation more effective than IA cell implantation for reducing all‐cause mortality, amputation rate, number of participants with any reduction in rest pain score, and number of healing ulcers and for improving lower limb perfusion in patients with critical lower limb ischaemia?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with critical lower limb ischaemia<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> IM injection<br/> <b>Comparison:</b> IA injection </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IA injection</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with IM injection</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality</p> <p>Assessed during in‐patient stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three RCTs with a total of 100 participants reported 9 deaths (<a href="./references#CD010747-bbs2-0001" title="GuYQ , ZhangJ , GuoLR , QiLX , ZhangSW , XuJ , et al. Transplantation of autologous bone marrow mononuclear cells for patients with lower limb ischemia. Chinese Medical Journal2008;121(11):963‐7. [PUBMED: 18706241] ">Gu 2008</a>; <a href="./references#CD010747-bbs2-0003" title="KlepanecA , MistrikM , AltanerC , ValachovicovaM , OlejarovaI , SlyskoR , et al. No difference in intra‐arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplantation2012;21(9):1909‐18. [PUBMED: 22472173] MadaricJ , KlepanecA , MistrikM , AltanerC , ValachovicovaM , NecpalR , et al. Autologous bone marrow cells transplantation in patients with advanced critical limb ischemia: no difference in intra‐arterial and intramuscular application. Journal of the American College of Cardiology2011;57(14):E1473. ">Klepanec 2012</a>; <a href="./references#CD010747-bbs2-0006" title="VanTongerenRB , HammingJF , FibbeWE , VanWeelV , FrerichsSJ , StiggelboutAM , et al. Intramuscular or combined intramuscular/intra‐arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. Journal of Cardiovascular Surgery2008;49(1):51‐8. [PUBMED: 18212687] ">Van Tongeren 2008</a>). None of the 3 studies reported all‐cause mortality according to treatment group. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Amputation rate</p> <p>Assessed during in‐patient stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.80<br/> (0.54 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>95<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> LOW<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000<br/> (270 to 590) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>636 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>509 per 1000<br/> (344 to 751) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Wound/ulcer healing: number of participants with healing ulcer</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.13<br/> (0.73 to 1.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>619 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000<br/> (452 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>619 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>699 per 1000<br/> (452 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Reduction in rest pain: number of participants with reduction in rest pain score</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.22<br/> (0.91 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>32<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>765 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>933 per 1000<br/> (696 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>765 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>933 per 1000<br/> (696 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Improvement in lower limb perfusion: number of participants with increased ABI</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.93<br/> (0.43 to 2.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1000<br/> (191 to 889) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41</p> <p>3 per 1000<br/> (191 to 889) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Improvement in lower limb perfusion: number of participants with improved TcO₂ reading</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.22<br/> (0.86 to 1.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>62<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>b,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>613 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>748 per 1000<br/> (527 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate**</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>603 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>735 per 1000<br/> (518 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>** We took the median control group event rate for the outcome as "moderate risk".</b><br/> ABI: ankle‐brachial index; CI: confidence interval; IA: intra‐arterial; IM: intramuscular; RCT: randomised controlled trial; RR: risk ratio; TcO₂: transcutaneous oxygen tension. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>All three included studies had unclear risk of selection bias and high risk of performance biases (participants and personnel were not blinded). Quality of evidence was downgraded by one level.<br/> <sup>b</sup>The 95% CI for the effect estimate from a single small study ranges from an effect size that clearly favours IM injection to an effect size that clearly favours IA injection. Quality of evidence was downgraded by one level on the basis of imprecision.<br/> <sup>c</sup>The single included study had unclear risk of selection bias and high risk of performance bias (participants and personnel were not blinded). Quality of evidence was downgraded by one level.<br/> <sup>d</sup>An improvement in ABI might not correlate strongly with an improvement in clinical symptoms and functions. Quality of evidence was downgraded by one level.<br/> <sup>e</sup>The two included studies had unclear risk of selection bias and high risk of performance bias (participants and personnel were not blinded). Quality of evidence was downgraded by one level.<br/> <sup>f</sup>An improvement in TcPO₂ reading might not correlate with an improvement in clinical symptoms and functions. Quality of evidence was downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">IM injection compared to IA injection for critical lower limb ischaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/full#CD010747-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010747-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">BM‐MNCs vs mPBSCs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Amputation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.45, 5.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Wound/ulcer healing: number of participants with healing ulcers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.44, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Wound/ulcer healing: change in ulcer size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.06 [‐5.35, 3.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Reduction in rest pain: number of participants with any reduction in rest pain score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Reduction in rest pain: rest pain score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.90, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Improvement in lower limb perfusion: number of participants with increased ABI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.71, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Improvement in lower limb perfusion: ABI score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.09, ‐0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Improvement in lower limb perfusion: TcO₂ reading in mmHg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.41, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Improvement in ischaemic symptoms: PFWD in metres at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>33.05 [‐37.69, 103.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">BM‐MNCs vs mPBSCs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010747-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">BM‐MNCs vs BM‐MSCs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Amputation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Wound/ulcer healing: number of participants with healing ulcers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [1.02, 3.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Reduction in rest pain: rest pain score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.61, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Improvement in lower limb perfusion: ABI score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Improvement in lower limb perfusion: TcO₂ reading in mmHg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.0 [3.46, 12.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Improvement in ischaemic symptoms: PFWT in minutes at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐0.01, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Improvement in vascularity and blood supply: number of participants with increase in numbers of collateral vessels <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.12, 3.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">BM‐MNCs vs BM‐MSCs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010747-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Low cell dose vs high cell dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Amputation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.87, 11.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Low cell dose vs high cell dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010747-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Route of injection: IM injection vs IA injection</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Amputation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.54, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Wound/ulcer healing: number of participants with healing ulcer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.73, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Reduction in rest pain: number of participants with reduction in rest pain score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.91, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Improvement in lower limb perfusion: number of participants with increased ABI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.43, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Improvement in lower limb perfusion: ABI score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.37, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Improvement in lower limb perfusion: number of participants with improved TcO₂ reading <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.86, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Improvement in vascularity and blood supply: number of participants with increase in numbers of collateral vessels <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.40, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Route of injection: IM injection vs IA injection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010747.pub2/references#CD010747-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010747.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010747-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010747-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010747-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD010747-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD010747-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD010747-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010747-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010747\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010747\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010747\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010747\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010747\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010747.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010747.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010747.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010747.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010747.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718152778"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010747.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718152782"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010747.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc95e7895f3fd',t:'MTc0MDcxODE1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 